{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T20:48:01Z","timestamp":1791406081838,"version":"4.3.3"},"reference-count":292,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,2,15]],"date-time":"2021-02-15T00:00:00Z","timestamp":1613347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,2,15]],"date-time":"2021-02-15T00:00:00Z","timestamp":1613347200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA219495"],"award-info":[{"award-number":["R01CA219495"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA230628"],"award-info":[{"award-number":["R01CA230628"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["R01GM128055"],"award-info":[{"award-number":["R01GM128055"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Metastasis"],"published-print":{"date-parts":[[2021,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Epithelial ovarian cancer (EOC) is a leading cause of cancer-related death in women. Late-stage diagnosis with significant tumor burden, accompanied by recurrence and chemotherapy resistance, contributes to this poor prognosis. These morbidities are known to be tied to events associated with epithelial-mesenchymal transition (EMT) in cancer. During EMT, localized tumor cells alter their polarity, cell\u2013cell junctions, cell\u2013matrix interactions, acquire motility and invasiveness and an exaggerated potential for metastatic spread. Key triggers for EMT include the Transforming Growth Factor-\u03b2 (TGF\u03b2) family of growth factors which are actively produced by a wide array of cell types within a specific tumor and metastatic environment. Although TGF\u03b2 can act as either a tumor suppressor or promoter in cancer, TGF\u03b2 exhibits its pro-tumorigenic functions at least in part via EMT. TGF\u03b2 regulates EMT both at the transcriptional and post-transcriptional levels as outlined here. Despite recent advances in TGF\u03b2 based therapeutics, limited progress has been seen for ovarian cancers that are in much need of new therapeutic strategies. Here, we summarize and discuss several recent insights into the underlying signaling mechanisms of the TGF\u03b2 isoforms in EMT in the unique metastatic environment of EOCs and the current therapeutic interventions that may be relevant.<\/jats:p>","DOI":"10.1007\/s10585-021-10077-z","type":"journal-article","created":{"date-parts":[[2021,2,18]],"date-time":"2021-02-18T17:14:32Z","timestamp":1613668472000},"page":"139-161","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":72,"title":["TGF\u03b2 signaling networks in ovarian cancer progression and plasticity"],"prefix":"10.1007","volume":"38","author":[{"given":"Asha","family":"Kumari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zainab","family":"Shonibare","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehri","family":"Monavarian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca C.","family":"Arend","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nam Y.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gareth J.","family":"Inman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5478-0098","authenticated-orcid":false,"given":"Karthikeyan","family":"Mythreye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,2,15]]},"reference":[{"issue":"2","key":"10077_CR1","doi-asserted-by":"crossref","first-page":"a011908","DOI":"10.1101\/cshperspect.a011908","volume":"4","author":"P Nistic\u00f2","year":"2012","unstructured":"Nistic\u00f2 P, Bissell MJ, Radisky DC (2012) Epithelial-mesenchymal transition: general principles and pathological relevance with special emphasis on the role of matrix metalloproteinases. Cold Spring Harb Perspect Biol 4(2):a011908","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"1","key":"10077_CR2","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1159\/000147748","volume":"154","author":"ED Hay","year":"1995","unstructured":"Hay ED (1995) An overview of epithelio-mesenchymal transformation. Cells Tissues Organs 154(1):8\u201320","journal-title":"Cells Tissues Organs"},{"issue":"2","key":"10077_CR3","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s10911-010-9178-9","volume":"15","author":"DS Micalizzi","year":"2010","unstructured":"Micalizzi DS, Farabaugh SM, Ford HL (2010) Epithelial-mesenchymal transition in cancer: parallels between normal development and tumor progression. J Mammary Gland Biol Neoplasia 15(2):117\u2013134","journal-title":"J Mammary Gland Biol Neoplasia"},{"issue":"6","key":"10077_CR4","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1172\/JCI39104","volume":"119","author":"R Kalluri","year":"2009","unstructured":"Kalluri R, Weinberg RA (2009) The basics of epithelial-mesenchymal transition. J Clin Invest 119(6):1420\u20131428","journal-title":"J Clin Invest"},{"issue":"1","key":"10077_CR5","doi-asserted-by":"crossref","first-page":"5","DOI":"10.21037\/atm.2016.12.67","volume":"5","author":"H-M Jeon","year":"2017","unstructured":"Jeon H-M, Lee J (2017) MET: roles in epithelial-mesenchymal transition and cancer stemness. Ann Transl Med 5(1):5","journal-title":"Ann Transl Med"},{"issue":"6","key":"10077_CR6","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.devcel.2018.05.027","volume":"45","author":"NM Aiello","year":"2018","unstructured":"Aiello NM et al (2018) EMT subtype influences epithelial plasticity and mode of cell migration. Dev Cell 45(6):681\u2013695","journal-title":"Dev Cell"},{"issue":"3","key":"10077_CR7","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.tcb.2018.12.001","volume":"29","author":"I Pastushenko","year":"2019","unstructured":"Pastushenko I, Blanpain C (2019) EMT transition states during tumor progression and metastasis. Trends Cell Biol 29(3):212\u2013226","journal-title":"Trends Cell Biol"},{"key":"10077_CR8","doi-asserted-by":"crossref","first-page":"25","DOI":"10.21037\/sci.2019.08.08","volume":"6","author":"VL Chin","year":"2019","unstructured":"Chin VL, Lim CL (2019) Epithelial-mesenchymal plasticity-engaging stemness in an interplay of phenotypes. Stem Cell Investig 6:25\u201327","journal-title":"Stem Cell Investig"},{"issue":"6","key":"10077_CR9","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nrc2131","volume":"7","author":"H Peinado","year":"2007","unstructured":"Peinado H, Olmeda D, Cano A (2007) Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype? Nature Rev Cancer 7(6):415\u2013428","journal-title":"Nature Rev Cancer"},{"issue":"13","key":"10077_CR10","doi-asserted-by":"crossref","first-page":"2827","DOI":"10.1242\/jcs.01145","volume":"117","author":"H Peinado","year":"2004","unstructured":"Peinado H et al (2004) Snail and E47 repressors of E-cadherin induce distinct invasive and angiogenic properties in vivo. J Cell Sci 117(13):2827\u20132839","journal-title":"J Cell Sci"},{"issue":"6","key":"10077_CR11","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1038\/ncb2976","volume":"16","author":"A Puisieux","year":"2014","unstructured":"Puisieux A, Brabletz T, Caramel J (2014) Oncogenic roles of EMT-inducing transcription factors. Nature Cell Biol 16(6):488\u2013494","journal-title":"Nature Cell Biol"},{"issue":"7","key":"10077_CR12","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/j.cell.2004.06.006","volume":"117","author":"J Yang","year":"2004","unstructured":"Yang J et al (2004) Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell 117(7):927\u2013939","journal-title":"Cell"},{"issue":"4","key":"10077_CR13","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/j.cell.2008.03.027","volume":"133","author":"SA Mani","year":"2008","unstructured":"Mani SA et al (2008) The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133(4):704\u2013715","journal-title":"Cell"},{"issue":"16","key":"10077_CR14","doi-asserted-by":"crossref","first-page":"4769","DOI":"10.1158\/1078-0432.CCR-06-2926","volume":"13","author":"B Hotz","year":"2007","unstructured":"Hotz B et al (2007) Epithelial to mesenchymal transition: expression of the regulators snail, slug, and twist in pancreatic cancer. Clin Cancer Res 13(16):4769\u20134776","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10077_CR15","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1038\/ncb3513","volume":"19","author":"AM Krebs","year":"2017","unstructured":"Krebs AM et al (2017) The EMT-activator Zeb1 is a key factor for cell plasticity and promotes metastasis in pancreatic cancer. Nature Cell Biol 19(5):518\u2013529","journal-title":"Nature Cell Biol"},{"issue":"7579","key":"10077_CR16","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/nature16064","volume":"527","author":"X Zheng","year":"2015","unstructured":"Zheng X et al (2015) Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer. Nature 527(7579):525\u2013530","journal-title":"Nature"},{"issue":"1","key":"10077_CR17","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.bj.2019.11.002","volume":"43","author":"N Aceto","year":"2020","unstructured":"Aceto N (2020) Bring along your friends: Homotypic and heterotypic circulating tumor cell clustering to accelerate metastasis. Biomed J 43(1):18\u201323","journal-title":"Biomed J"},{"key":"10077_CR18","doi-asserted-by":"crossref","first-page":"28587","DOI":"10.1038\/srep28587","volume":"6","author":"S Imani","year":"2016","unstructured":"Imani S et al (2016) Prognostic value of EMT-inducing transcription factors (EMT-TFs) in metastatic breast cancer: a systematic review and meta-analysis. Sci Rep 6:28587","journal-title":"Sci Rep"},{"issue":"6\u20137","key":"10077_CR19","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1002\/emmm.200900043","volume":"1","author":"JM Lopez-Novoa","year":"2009","unstructured":"Lopez-Novoa JM, Nieto MA (2009) Inflammation and EMT: an alliance towards organ fibrosis and cancer progression. EMBO Mol Med 1(6\u20137):303\u2013314","journal-title":"EMBO Mol Med"},{"issue":"3","key":"10077_CR20","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1038\/nrm3758","volume":"15","author":"S Lamouille","year":"2014","unstructured":"Lamouille S, Xu J, Derynck R (2014) Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol 15(3):178\u2013196","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"1","key":"10077_CR21","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.canlet.2013.02.048","volume":"341","author":"CD Morrison","year":"2013","unstructured":"Morrison CD, Parvani JG, Schiemann WP (2013) The relevance of the TGF-beta paradox to EMT-MET programs. Cancer Lett 341(1):30\u201340","journal-title":"Cancer Lett"},{"issue":"11","key":"10077_CR22","doi-asserted-by":"crossref","first-page":"2767","DOI":"10.3390\/ijms20112767","volume":"20","author":"Y Hao","year":"2019","unstructured":"Hao Y, Baker D, Ten Dijke P (2019) TGF-\u03b2-mediated epithelial-mesenchymal transition and cancer metastasis. Int J Mol Sci 20(11):2767","journal-title":"Int J Mol Sci"},{"issue":"9","key":"10077_CR23","doi-asserted-by":"crossref","first-page":"5258","DOI":"10.1073\/pnas.77.9.5258","volume":"77","author":"GJ Todaro","year":"1980","unstructured":"Todaro GJ, Fryling C, De Larco JE (1980) Transforming growth factors produced by certain human tumor cells: polypeptides that interact with epidermal growth factor receptors. Proc Natl Acad Sci 77(9):5258\u20135262","journal-title":"Proc Natl Acad Sci"},{"issue":"5611","key":"10077_CR24","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1038\/267526a0","volume":"267","author":"GJ Todaro","year":"1977","unstructured":"Todaro GJ et al (1977) MSA and EGF receptors on saroma virus transformed cells and human fibrosarcoma cells in culture. Nature 267(5611):526\u2013528","journal-title":"Nature"},{"key":"10077_CR25","doi-asserted-by":"crossref","first-page":"874065","DOI":"10.1155\/2014\/874065","volume":"2014","author":"B Zhao","year":"2014","unstructured":"Zhao B, Chen Y-G (2014) Regulation of TGF-\u03b2 signal transduction. Scientifica 2014:874065","journal-title":"Scientifica"},{"issue":"5581","key":"10077_CR26","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/264026a0","volume":"264","author":"GJ Todaro","year":"1976","unstructured":"Todaro GJ, De Larco JE, Cohen S (1976) Transformation by murine and feline sarcoma viruses specifically blocks binding of epidermal growth factor to cells. Nature 264(5581):26\u201331","journal-title":"Nature"},{"issue":"8","key":"10077_CR27","doi-asserted-by":"crossref","first-page":"4001","DOI":"10.1073\/pnas.75.8.4001","volume":"75","author":"JE de Larco","year":"1978","unstructured":"de Larco JE, Todaro GJ (1978) Growth factors from murine sarcoma virus-transformed cells. Proc Natl Acad Sci 75(8):4001\u20134005","journal-title":"Proc Natl Acad Sci"},{"issue":"9","key":"10077_CR28","doi-asserted-by":"crossref","first-page":"5339","DOI":"10.1073\/pnas.78.9.5339","volume":"78","author":"AB Roberts","year":"1981","unstructured":"Roberts AB et al (1981) New class of transforming growth factors potentiated by epidermal growth factor: isolation from non-neoplastic tissues. Proc Natl Acad Sci 78(9):5339\u20135343","journal-title":"Proc Natl Acad Sci"},{"issue":"7","key":"10077_CR29","doi-asserted-by":"crossref","first-page":"a021865","DOI":"10.1101\/cshperspect.a021865","volume":"8","author":"HL Moses","year":"2016","unstructured":"Moses HL, Roberts AB, Derynck R (2016) The discovery and early days of TGF-\u03b2: a historical perspective. Cold Spring Harb Perspect Biol 8(7):a021865","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"3","key":"10077_CR30","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/BF01570787","volume":"12","author":"D Fujii","year":"1986","unstructured":"Fujii D et al (1986) Transforming growth factor beta gene maps to human chromosome 19 long arm and to mouse chromosome 7. Somat Cell Mol Genet 12(3):281\u2013288","journal-title":"Somat Cell Mol Genet"},{"issue":"4","key":"10077_CR31","first-page":"323","volume":"3","author":"DE Barton","year":"1988","unstructured":"Barton DE et al (1988) Chromosomal mapping of genes for transforming growth factors beta 2 and beta 3 in man and mouse: dispersion of TGF-beta gene family. Oncogene Res 3(4):323\u2013331","journal-title":"Oncogene Res"},{"issue":"11","key":"10077_CR32","doi-asserted-by":"crossref","first-page":"7155","DOI":"10.1016\/S0021-9258(18)32345-7","volume":"258","author":"RK Assoian","year":"1983","unstructured":"Assoian RK et al (1983) Transforming growth factor-beta in human platelets. Identification of a major storage site, purification, and characterization. J Biol Chem 258(11):7155\u20137160","journal-title":"J Biol Chem"},{"issue":"6659","key":"10077_CR33","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/37284","volume":"390","author":"CH Heldin","year":"1997","unstructured":"Heldin CH, Miyazono K, ten Dijke P (1997) TGF-beta signalling from cell membrane to nucleus through SMAD proteins. Nature 390(6659):465\u2013471","journal-title":"Nature"},{"issue":"3","key":"10077_CR34","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.cytogfr.2005.01.009","volume":"16","author":"K Miyazono","year":"2005","unstructured":"Miyazono K, Maeda S, Imamura T (2005) BMP receptor signaling: transcriptional targets, regulation of signals, and signaling cross-talk. Cytokine Growth Factor Rev 16(3):251\u2013263","journal-title":"Cytokine Growth Factor Rev"},{"issue":"12","key":"10077_CR35","doi-asserted-by":"crossref","first-page":"e022103","DOI":"10.1101\/cshperspect.a022103","volume":"8","author":"AP Hinck","year":"2016","unstructured":"Hinck AP, Mueller TD, Springer TA (2016) Structural biology and evolution of the TGF-beta family. Cold Spring Harb Perspect Biol 8(12):e022103","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"9","key":"10077_CR36","doi-asserted-by":"crossref","first-page":"7409","DOI":"10.1074\/jbc.R400029200","volume":"280","author":"DB Rifkin","year":"2005","unstructured":"Rifkin DB (2005) Latent transforming growth factor-beta (TGF-beta) binding proteins: orchestrators of TGF-beta availability. J Biol Chem 280(9):7409\u20137412","journal-title":"J Biol Chem"},{"issue":"5","key":"10077_CR37","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1083\/jcb.200312172","volume":"165","author":"JP Annes","year":"2004","unstructured":"Annes JP et al (2004) Integrin alphaVbeta6-mediated activation of latent TGF-beta requires the latent TGF-beta binding protein-1. J Cell Biol 165(5):723\u2013734","journal-title":"J Cell Biol"},{"issue":"1\u20133","key":"10077_CR38","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/S0014-5793(02)02648-0","volume":"517","author":"Y Chen","year":"2002","unstructured":"Chen Y et al (2002) Latent TGF-beta binding protein-3 (LTBP-3) requires binding to TGF-beta for secretion. FEBS Lett 517(1\u20133):277\u2013280","journal-title":"FEBS Lett"},{"issue":"2","key":"10077_CR39","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/S0002-9440(10)63681-4","volume":"163","author":"L Fjellbirkeland","year":"2003","unstructured":"Fjellbirkeland L et al (2003) Integrin alphavbeta8-mediated activation of transforming growth factor-beta inhibits human airway epithelial proliferation in intact bronchial tissue. Am J Pathol 163(2):533\u2013542","journal-title":"Am J Pathol"},{"issue":"6","key":"10077_CR40","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1172\/JCI27183","volume":"116","author":"RG Jenkins","year":"2006","unstructured":"Jenkins RG et al (2006) Ligation of protease-activated receptor 1 enhances alpha(v)beta6 integrin-dependent TGF-beta activation and promotes acute lung injury. J Clin Invest 116(6):1606\u20131614","journal-title":"J Clin Invest"},{"issue":"7351","key":"10077_CR41","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/nature10152","volume":"474","author":"M Shi","year":"2011","unstructured":"Shi M et al (2011) Latent TGF-\u03b2 structure and activation. Nature 474(7351):343\u2013349","journal-title":"Nature"},{"issue":"7","key":"10077_CR42","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/S0092-8674(00)81460-9","volume":"93","author":"SE Crawford","year":"1998","unstructured":"Crawford SE et al (1998) Thrombospondin-1 is a major activator of TGF-\u03b21 in vivo. Cell 93(7):1159\u20131170","journal-title":"Cell"},{"issue":"6417","key":"10077_CR43","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1126\/science.aau2909","volume":"362","author":"S Li\u00e9nart","year":"2018","unstructured":"Li\u00e9nart S et al (2018) Structural basis of latent TGF-\u03b21 presentation and activation by GARP on human regulatory T cells. Science 362(6417):952\u2013956","journal-title":"Science"},{"issue":"1","key":"10077_CR44","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cytogfr.2003.10.004","volume":"15","author":"M de Caestecker","year":"2004","unstructured":"de Caestecker M (2004) The transforming growth factor-beta superfamily of receptors. Cytokine Growth Factor Rev 15(1):1\u201311","journal-title":"Cytokine Growth Factor Rev"},{"issue":"1","key":"10077_CR45","first-page":"3","volume":"143","author":"AB Kulkarni","year":"1993","unstructured":"Kulkarni AB, Karlsson S (1993) Transforming growth factor-beta 1 knockout mice. A mutation in one cytokine gene causes a dramatic inflammatory disease. Am J Pathol 143(1):3","journal-title":"Am J Pathol"},{"issue":"6","key":"10077_CR46","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1242\/dev.121.6.1845","volume":"121","author":"MC Dickson","year":"1995","unstructured":"Dickson MC et al (1995) Defective haematopoiesis and vasculogenesis in transforming growth factor-beta 1 knock out mice. Development 121(6):1845\u20131854","journal-title":"Development"},{"issue":"17","key":"10077_CR47","doi-asserted-by":"crossref","first-page":"3869","DOI":"10.1242\/dev.126.17.3869","volume":"126","author":"Y Taya","year":"1999","unstructured":"Taya Y, O\u2019Kane S, Ferguson M (1999) Pathogenesis of cleft palate in TGF-beta3 knockout mice. Development 126(17):3869\u20133879","journal-title":"Development"},{"issue":"4","key":"10077_CR48","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/ng1295-415","volume":"11","author":"V Kaartinen","year":"1995","unstructured":"Kaartinen V et al (1995) Abnormal lung development and cleft palate in mice lacking TGF\u2013\u03b23 indicates defects of epithelial\u2013mesenchymal interaction. Nature Genet 11(4):415\u2013421","journal-title":"Nature Genet"},{"issue":"13","key":"10077_CR49","doi-asserted-by":"crossref","first-page":"2659","DOI":"10.1242\/dev.124.13.2659","volume":"124","author":"LP Sanford","year":"1997","unstructured":"Sanford LP et al (1997) TGFbeta2 knockout mice have multiple developmental defects that are non-overlapping with other TGFbeta knockout phenotypes. Development 124(13):2659\u20132670","journal-title":"Development"},{"issue":"9","key":"10077_CR50","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1242\/jcs.003129","volume":"120","author":"A Nawshad","year":"2007","unstructured":"Nawshad A et al (2007) TGF\u03b23 inhibits E-cadherin gene expression in palate medial-edge epithelial cells through a Smad2-Smad4-LEF1 transcription complex. J Cell Sci 120(9):1646\u20131653","journal-title":"J Cell Sci"},{"issue":"2","key":"10077_CR51","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1006\/dbio.1996.0070","volume":"174","author":"CB Brown","year":"1996","unstructured":"Brown CB et al (1996) Antibodies to the type II TGF\u03b2 receptor block cell activation and migration during atrioventricular cushion transformation in the heart. Dev Biol 174(2):248\u2013257","journal-title":"Dev Biol"},{"issue":"4","key":"10077_CR52","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1002\/dvdy.1154","volume":"221","author":"AS Boyer","year":"2001","unstructured":"Boyer AS, Runyan RB (2001) TGFbeta type III and TGFbeta type II receptors have distinct activities during epithelial-mesenchymal cell transformation in the embryonic heart. Dev Dyn 221(4):454\u2013459","journal-title":"Dev Dyn"},{"key":"10077_CR53","volume-title":"Regulation of TGFB2 expression during EMT in lung epithelial cells","author":"A Salib","year":"2017","unstructured":"Salib A (2017) Regulation of TGFB2 expression during EMT in lung epithelial cells. Western Sydney University, Australia"},{"issue":"4","key":"10077_CR54","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1083\/jcb.115.4.1091","volume":"115","author":"RW Pelton","year":"1991","unstructured":"Pelton RW et al (1991) Immunohistochemical localization of TGF beta 1, TGF beta 2, and TGF beta 3 in the mouse embryo: expression patterns suggest multiple roles during embryonic development. J Cell Biol 115(4):1091\u20131105","journal-title":"J Cell Biol"},{"issue":"3","key":"10077_CR55","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/0955-2235(90)90002-2","volume":"2","author":"RJ Akhurst","year":"1990","unstructured":"Akhurst RJ et al (1990) Transforming growth factor betas in mammalian embryogenesis. Prog Growth Factor Res 2(3):153\u2013168","journal-title":"Prog Growth Factor Res"},{"issue":"1\u20132","key":"10077_CR56","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.mce.2008.08.017","volume":"294","author":"MA Memon","year":"2008","unstructured":"Memon MA et al (2008) Transforming growth factor beta (TGF\u03b21, TGF\u03b22 and TGF\u03b23) null-mutant phenotypes in embryonic gonadal development. Mol Cell Endocrinol 294(1\u20132):70\u201380","journal-title":"Mol Cell Endocrinol"},{"issue":"3","key":"10077_CR57","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1002\/(SICI)1097-0142(19990201)85:3<658::AID-CNCR16>3.0.CO;2-M","volume":"85","author":"RE Bristow","year":"1999","unstructured":"Bristow RE et al (1999) Altered expression of transforming growth factor-\u03b2 ligands and receptors in primary and recurrent ovarian carcinoma. Cancer 85(3):658\u2013668","journal-title":"Cancer"},{"issue":"2","key":"10077_CR58","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S0303-7207(01)00584-6","volume":"182","author":"E Nilsson","year":"2001","unstructured":"Nilsson E et al (2001) Expression and action of transforming growth factor beta (TGF\u03b21, TGF\u03b22, TGF\u03b23) in normal bovine ovarian surface epithelium and implications for human ovarian cancer. Mol Cell Endocrinol 182(2):145\u2013155","journal-title":"Mol Cell Endocrinol"},{"issue":"4","key":"10077_CR59","first-page":"1177","volume":"79","author":"Y Zhao","year":"1994","unstructured":"Zhao Y, Chegini N, Flanders KC (1994) Human fallopian tube expresses transforming growth factor (TGF beta) isoforms, TGF beta type I-III receptor messenger ribonucleic acid and protein, and contains [125I] TGF beta-binding sites. J Clin Endocrinol Metab 79(4):1177\u20131184","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"10077_CR60","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1210\/endo.134.3.8119153","volume":"134","author":"G Dissen","year":"1994","unstructured":"Dissen G et al (1994) Immature rat ovaries become revascularized rapidly after autotransplantation and show a gonadotropin-dependent increase in angiogenic factor gene expression. Endocrinology 134(3):1146\u20131154","journal-title":"Endocrinology"},{"issue":"11","key":"10077_CR61","doi-asserted-by":"crossref","first-page":"2978","DOI":"10.1158\/0008-5472.CAN-17-2316","volume":"78","author":"P Singh","year":"2018","unstructured":"Singh P et al (2018) Inhibin is a novel paracrine factor for tumor angiogenesis and metastasis. Cancer Res 78(11):2978\u20132989","journal-title":"Cancer Res"},{"issue":"11","key":"10077_CR62","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/j.neo.2015.11.003","volume":"17","author":"A Varadaraj","year":"2015","unstructured":"Varadaraj A et al (2015) Epigenetic regulation of GDF2 suppresses anoikis in ovarian and breast epithelia. Neoplasia 17(11):826\u2013838","journal-title":"Neoplasia"},{"issue":"3","key":"10077_CR63","first-page":"111","volume":"1","author":"H-M Chang","year":"2018","unstructured":"Chang H-M, Leung PCK (2018) Physiological roles of activins in the human ovary. J Bio-X Res 1(3):111\u2013119","journal-title":"J Bio-X Res"},{"issue":"12","key":"10077_CR64","doi-asserted-by":"crossref","first-page":"5463","DOI":"10.1210\/endo.137.12.8940372","volume":"137","author":"TK Woodruff","year":"1996","unstructured":"Woodruff TK et al (1996) Inhibin A and inhibin B are inversely correlated to follicle-stimulating hormone, yet are discordant during the follicular phase of the rat estrous cycle, and inhibin A is expressed in a sexually dimorphic manner. Endocrinology 137(12):5463\u20135467","journal-title":"Endocrinology"},{"issue":"14","key":"10077_CR65","doi-asserted-by":"crossref","first-page":"5082","DOI":"10.1073\/pnas.84.14.5082","volume":"84","author":"AJ Hsueh","year":"1987","unstructured":"Hsueh AJ et al (1987) Heterodimers and homodimers of inhibin subunits have different paracrine action in the modulation of luteinizing hormone-stimulated androgen biosynthesis. Proc Natl Acad Sci U S A 84(14):5082\u20135086","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6596","key":"10077_CR66","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/383168a0","volume":"383","author":"Y Zhang","year":"1996","unstructured":"Zhang Y et al (1996) Receptor-associated mad homologues synergize as effectors of the TGF-beta response. Nature 383(6596):168\u2013172","journal-title":"Nature"},{"issue":"6","key":"10077_CR67","doi-asserted-by":"crossref","first-page":"a021907","DOI":"10.1101\/cshperspect.a021907","volume":"8","author":"IB Robertson","year":"2016","unstructured":"Robertson IB, Rifkin DB (2016) Regulation of the bioavailability of TGF-\u03b2 and TGF-\u03b2-related proteins. Cold Spring Harb Perspect Biol 8(6):a021907","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"6","key":"10077_CR68","doi-asserted-by":"crossref","first-page":"4176","DOI":"10.1074\/jbc.M105105200","volume":"277","author":"S Bai","year":"2002","unstructured":"Bai S, Cao X (2002) A nuclear antagonistic mechanism of inhibitory smads in transforming growth factor-beta signaling. J Biol Chem 277(6):4176\u20134182","journal-title":"J Biol Chem"},{"issue":"8","key":"10077_CR69","doi-asserted-by":"crossref","first-page":"a021923","DOI":"10.1101\/cshperspect.a021923","volume":"8","author":"C Chang","year":"2016","unstructured":"Chang C (2016) Agonists and antagonists of TGF-\u03b2 family ligands. Cold Spring Harb Perspect Biol 8(8):a021923","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"8","key":"10077_CR70","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/j.cellsig.2010.01.016","volume":"22","author":"CE Gatza","year":"2010","unstructured":"Gatza CE, Oh SY, Blobe GC (2010) Roles for the type III TGF-beta receptor in human cancer. Cell Signal 22(8):1163\u20131174","journal-title":"Cell Signal"},{"issue":"3","key":"10077_CR71","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/0092-8674(87)90192-9","volume":"48","author":"S Cheifetz","year":"1987","unstructured":"Cheifetz S et al (1987) The transforming growth factor-beta system, a complex pattern of cross-reactive ligands and receptors. Cell 48(3):409\u2013415","journal-title":"Cell"},{"issue":"7","key":"10077_CR72","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1002\/pro.5560050705","volume":"5","author":"PR Mittl","year":"1996","unstructured":"Mittl PR et al (1996) The crystal structure of TGF-beta 3 and comparison to TGF-beta 2: implications for receptor binding. Protein Sci 5(7):1261\u20131271","journal-title":"Protein Sci"},{"issue":"14","key":"10077_CR73","doi-asserted-by":"crossref","first-page":"E2975","DOI":"10.1073\/pnas.1611428114","volume":"114","author":"CL Frick","year":"2017","unstructured":"Frick CL et al (2017) Sensing relative signal in the Tgf-beta\/Smad pathway. Proc Natl Acad Sci U S A 114(14):E2975\u2013E2982","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"22","key":"10077_CR74","doi-asserted-by":"crossref","first-page":"5483","DOI":"10.1021\/acs.jpcb.7b01867","volume":"121","author":"SM Nayeem","year":"2017","unstructured":"Nayeem SM et al (2017) Residues of alpha helix H3 determine distinctive features of transforming growth factor \u03b23. J Phys Chem B 121(22):5483\u20135498","journal-title":"J Phys Chem B"},{"issue":"8","key":"10077_CR75","doi-asserted-by":"crossref","first-page":"a022053","DOI":"10.1101\/cshperspect.a022053","volume":"8","author":"C-H Heldin","year":"2016","unstructured":"Heldin C-H, Moustakas A (2016) Signaling receptors for TGF-\u03b2 family members. Cold Spring Harb Perspect Biol 8(8):a022053","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"3","key":"10077_CR76","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1096\/fj.13-239178","volume":"28","author":"A Holtzhausen","year":"2013","unstructured":"Holtzhausen A et al (2013) Novel bone morphogenetic protein signaling through Smad2 and Smad3 to regulate cancer progression and development. FASEB J 28(3):1248\u20131267","journal-title":"FASEB J"},{"issue":"12","key":"10077_CR77","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1210\/mend-5-12-1887","volume":"5","author":"RM Lyons","year":"1991","unstructured":"Lyons RM et al (1991) Differential binding of transforming growth factor-\u03b21,-\u03b22, and-\u03b23 by fibroblasts and epithelial cells measured by affinity cross-linking of cell surface receptors. Mol Endocrinol 5(12):1887\u20131896","journal-title":"Mol Endocrinol"},{"issue":"6","key":"10077_CR78","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S0092-8674(03)00432-X","volume":"113","author":"Y Shi","year":"2003","unstructured":"Shi Y, Massagu\u00e9 J (2003) Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell 113(6):685\u2013700","journal-title":"Cell"},{"issue":"11","key":"10077_CR79","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.tibs.2005.09.003","volume":"30","author":"KC Kirkbride","year":"2005","unstructured":"Kirkbride KC, Ray BN, Blobe GC (2005) Cell-surface co-receptors: emerging roles in signaling and human disease. Trends Biochem Sci 30(11):611\u2013621","journal-title":"Trends Biochem Sci"},{"issue":"6488","key":"10077_CR80","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/370341a0","volume":"370","author":"JL Wrana","year":"1994","unstructured":"Wrana JL et al (1994) Mechanism of activation of the TGF-beta receptor. Nature 370(6488):341\u2013347","journal-title":"Nature"},{"issue":"28","key":"10077_CR81","doi-asserted-by":"crossref","first-page":"20603","DOI":"10.1074\/jbc.M702100200","volume":"282","author":"K Goto","year":"2007","unstructured":"Goto K et al (2007) Selective inhibitory effects of Smad6 on bone morphogenetic protein type I receptors. J Biol Chem 282(28):20603\u201320611","journal-title":"J Biol Chem"},{"issue":"6","key":"10077_CR82","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1083\/jcb.200106023","volume":"155","author":"A Hanyu","year":"2001","unstructured":"Hanyu A et al (2001) The N domain of Smad7 is essential for specific inhibition of transforming growth factor-beta signaling. J Cell Biol 155(6):1017\u20131027","journal-title":"J Cell Biol"},{"issue":"10","key":"10077_CR83","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1038\/nrm3434","volume":"13","author":"J Massagu\u00e9","year":"2012","unstructured":"Massagu\u00e9 J (2012) TGF\u03b2 signalling in context. Nat Rev Mol Cell Biol 13(10):616\u2013630","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10077_CR84","doi-asserted-by":"crossref","first-page":"e31756","DOI":"10.7554\/eLife.31756","volume":"7","author":"A Ramachandran","year":"2018","unstructured":"Ramachandran A et al (2018) TGF-beta uses a novel mode of receptor activation to phosphorylate SMAD1\/5 and induce epithelial-to-mesenchymal transition. Elife 7:e31756","journal-title":"Elife"},{"issue":"2","key":"10077_CR85","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/emboj.2008.266","volume":"28","author":"IM Liu","year":"2009","unstructured":"Liu IM et al (2009) TGFbeta-stimulated Smad1\/5 phosphorylation requires the ALK5 L45 loop and mediates the pro-migratory TGFbeta switch. EMBO J 28(2):88\u201398","journal-title":"EMBO J"},{"issue":"10","key":"10077_CR86","doi-asserted-by":"crossref","first-page":"a022079","DOI":"10.1101\/cshperspect.a022079","volume":"8","author":"CS Hill","year":"2016","unstructured":"Hill CS (2016) Transcriptional control by the SMADs. Cold Spring Harb Perspect Biol 8(10):a022079","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"5","key":"10077_CR87","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/S0092-8674(00)81600-1","volume":"94","author":"Y Shi","year":"1998","unstructured":"Shi Y et al (1998) Crystal structure of a Smad MH1 domain bound to DNA: insights on DNA binding in TGF-beta signaling. Cell 94(5):585\u2013594","journal-title":"Cell"},{"issue":"5","key":"10077_CR88","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1128\/MCB.17.5.2521","volume":"17","author":"RY Wu","year":"1997","unstructured":"Wu RY et al (1997) Heteromeric and homomeric interactions correlate with signaling activity and functional cooperativity of Smad3 and Smad4\/DPC4. Mol Cell Biol 17(5):2521\u20132528","journal-title":"Mol Cell Biol"},{"issue":"10","key":"10077_CR89","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1038\/nrm3434","volume":"13","author":"J Massague","year":"2012","unstructured":"Massague J (2012) TGFbeta signalling in context. Nat Rev Mol Cell Biol 13(10):616\u2013630","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"4","key":"10077_CR90","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.cell.2009.09.035","volume":"139","author":"C Alarcon","year":"2009","unstructured":"Alarcon C et al (2009) Nuclear CDKs drive Smad transcriptional activation and turnover in BMP and TGF-beta pathways. Cell 139(4):757\u2013769","journal-title":"Cell"},{"issue":"3","key":"10077_CR91","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.molcel.2009.09.043","volume":"36","author":"S Gao","year":"2009","unstructured":"Gao S et al (2009) Ubiquitin ligase Nedd4L targets activated Smad2\/3 to limit TGF-beta signaling. Mol Cell 36(3):457\u2013468","journal-title":"Mol Cell"},{"issue":"12","key":"10077_CR92","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1101\/gad.2060811","volume":"25","author":"E Arag\u00f3n","year":"2011","unstructured":"Arag\u00f3n E et al (2011) A Smad action turnover switch operated by WW domain readers of a phosphoserine code. Genes Dev 25(12):1275\u20131288","journal-title":"Genes Dev"},{"issue":"23","key":"10077_CR93","doi-asserted-by":"crossref","first-page":"6594","DOI":"10.1158\/0008-5472.CAN-18-1583","volume":"78","author":"J Liang","year":"2018","unstructured":"Liang J et al (2018) CDK8 selectively promotes the growth of colon cancer metastases in the liver by regulating gene expression of timp3 and matrix metalloproteinases. Cancer Res 78(23):6594\u20136606","journal-title":"Cancer Res"},{"issue":"35","key":"10077_CR94","doi-asserted-by":"crossref","first-page":"4792","DOI":"10.1038\/s41388-018-0316-y","volume":"37","author":"A Serrao","year":"2018","unstructured":"Serrao A et al (2018) Mediator kinase CDK8\/CDK19 drives YAP1-dependent BMP4-induced EMT in cancer. Oncogene 37(35):4792\u20134808","journal-title":"Oncogene"},{"issue":"8","key":"10077_CR95","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1038\/ncb1905","volume":"11","author":"T Vincent","year":"2009","unstructured":"Vincent T et al (2009) A SNAIL1\u2013SMAD3\/4 transcriptional repressor complex promotes TGF-\u03b2 mediated epithelial\u2013mesenchymal transition. Nature Cell Biol 11(8):943\u2013950","journal-title":"Nature Cell Biol"},{"issue":"3","key":"10077_CR96","doi-asserted-by":"crossref","first-page":"869","DOI":"10.3892\/ijo.2012.1535","volume":"41","author":"M Cao","year":"2012","unstructured":"Cao M et al (2012) MiR-23a regulates TGF-\u03b2-induced epithelial-mesenchymal transition by targeting E-cadherin in lung cancer cells. Int J Oncol 41(3):869\u2013875","journal-title":"Int J Oncol"},{"issue":"50","key":"10077_CR97","doi-asserted-by":"crossref","first-page":"5614","DOI":"10.1038\/onc.2013.322","volume":"32","author":"J Johansson","year":"2013","unstructured":"Johansson J et al (2013) MiR-155-mediated loss of C\/EBP\u03b2 shifts the TGF-\u03b2 response from growth inhibition to epithelial-mesenchymal transition, invasion and metastasis in breast cancer. Oncogene 32(50):5614\u20135624","journal-title":"Oncogene"},{"issue":"3","key":"10077_CR98","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/ncb2024","volume":"12","author":"L Ma","year":"2010","unstructured":"Ma L et al (2010) miR-9, a MYC\/MYCN-activated microRNA, regulates E-cadherin and cancer metastasis. Nature Cell Biol 12(3):247\u2013256","journal-title":"Nature Cell Biol"},{"issue":"2","key":"10077_CR99","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/cgt.2013.82","volume":"21","author":"X Han","year":"2014","unstructured":"Han X et al (2014) Critical role of miR-10b in transforming growth factor-\u03b21-induced epithelial\u2013mesenchymal transition in breast cancer. Cancer Gene Ther 21(2):60\u201367","journal-title":"Cancer Gene Ther"},{"issue":"11","key":"10077_CR100","doi-asserted-by":"crossref","first-page":"3031","DOI":"10.1158\/0008-5472.CAN-13-2193","volume":"74","author":"Q Song","year":"2014","unstructured":"Song Q et al (2014) miR-483\u20135p promotes invasion and metastasis of lung adenocarcinoma by targeting RhoGDI1 and ALCAM. Cancer Res 74(11):3031\u20133042","journal-title":"Cancer Res"},{"issue":"10","key":"10077_CR101","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.3748\/wjg.v23.i10.1816","volume":"23","author":"C Sun","year":"2017","unstructured":"Sun C et al (2017) miR-34a mediates oxaliplatin resistance of colorectal cancer cells by inhibiting macroautophagy via transforming growth factor-\u03b2\/Smad4 pathway. World J Gastroenterol 23(10):1816","journal-title":"World J Gastroenterol"},{"issue":"1","key":"10077_CR102","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1080\/21691401.2019.1703724","volume":"48","author":"X Zhang","year":"2020","unstructured":"Zhang X et al (2020) miR-324\u20135p inhibits gallbladder carcinoma cell metastatic behaviours by downregulation of transforming growth factor beta 2 expression. Artificial Cells Nanomed Biotech 48(1):315\u2013324","journal-title":"Artificial Cells Nanomed Biotech"},{"key":"10077_CR103","doi-asserted-by":"crossref","first-page":"2977","DOI":"10.1038\/ncomms3977","volume":"5","author":"A Parikh","year":"2014","unstructured":"Parikh A et al (2014) microRNA-181a has a critical role in ovarian cancer progression through the regulation of the epithelial\u2013mesenchymal transition. Nature Commun 5:2977","journal-title":"Nature Commun"},{"issue":"6","key":"10077_CR104","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.3390\/ijms18061207","volume":"18","author":"P-W Choi","year":"2017","unstructured":"Choi P-W, Ng S-W (2017) The functions of microRNA-200 family in ovarian cancer: beyond epithelial-mesenchymal transition. Int J Mol Sci 18(6):1207","journal-title":"Int J Mol Sci"},{"issue":"3","key":"10077_CR105","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1038\/ncb2029","volume":"12","author":"A Chaudhury","year":"2010","unstructured":"Chaudhury A et al (2010) TGF-beta-mediated phosphorylation of hnRNP E1 induces EMT via transcript-selective translational induction of Dab2 and ILEI. Nature Cell Biol 12(3):286\u2013293","journal-title":"Nature Cell Biol"},{"issue":"4","key":"10077_CR106","doi-asserted-by":"crossref","first-page":"3748","DOI":"10.18632\/oncotarget.6387","volume":"7","author":"IJ Matouk","year":"2016","unstructured":"Matouk IJ et al (2016) The role of the oncofetal H19 lncRNA in tumor metastasis: orchestrating the EMT-MET decision. Oncotarget 7(4):3748","journal-title":"Oncotarget"},{"key":"10077_CR107","doi-asserted-by":"crossref","first-page":"427","DOI":"10.2147\/OTT.S149908","volume":"11","author":"J Li","year":"2018","unstructured":"Li J et al (2018) Long noncoding RNA H19 promotes transforming growth factor-\u03b2-induced epithelial\u2013mesenchymal transition by acting as a competing endogenous RNA of miR-370-3p in ovarian cancer cells. OncoTargets Ther 11:427","journal-title":"OncoTargets Ther"},{"key":"10077_CR108","doi-asserted-by":"publisher","DOI":"10.1042\/BSR20180936","author":"J Ma","year":"2018","unstructured":"Ma J, Xue M (2018) LINK-A lncRNA promotes migration and invasion of ovarian carcinoma cells by activating TGF-\u03b2 pathway. Biosci Rep. https:\/\/doi.org\/10.1042\/BSR20180936","journal-title":"Biosci Rep"},{"issue":"1","key":"10077_CR109","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1038\/s41467-017-01781-0","volume":"8","author":"R Mitra","year":"2017","unstructured":"Mitra R et al (2017) Decoding critical long non-coding RNA in ovarian cancer epithelial-to-mesenchymal transition. Nat Commun 8(1):1604","journal-title":"Nat Commun"},{"key":"10077_CR110","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.canlet.2018.08.009","volume":"436","author":"Y Wang","year":"2018","unstructured":"Wang Y et al (2018) TGF-\u03b2-induced STAT3 overexpression promotes human head and neck squamous cell carcinoma invasion and metastasis through malat1\/miR-30a interactions. Cancer Lett 436:52\u201362","journal-title":"Cancer Lett"},{"issue":"1","key":"10077_CR111","doi-asserted-by":"crossref","first-page":"e0228160","DOI":"10.1371\/journal.pone.0228160","volume":"15","author":"J Zhang","year":"2020","unstructured":"Zhang J et al (2020) The long-noncoding RNA MALAT1 regulates TGF-\u03b2\/Smad signaling through formation of a lncRNA-protein complex with Smads, SETD2 and PPM1A in hepatic cells. PLoS ONE 15(1):e0228160","journal-title":"PLoS ONE"},{"issue":"2","key":"10077_CR112","first-page":"1093","volume":"40","author":"X Zhang","year":"2018","unstructured":"Zhang X et al (2018) Long non-coding RNA PVT1 promotes epithelial-mesenchymal transition via the TGF-\u03b2\/Smad pathway in pancreatic cancer cells. Oncology Rep 40(2):1093\u20131102","journal-title":"Oncology Rep"},{"issue":"5","key":"10077_CR113","doi-asserted-by":"crossref","first-page":"101042831770575","DOI":"10.1177\/1010428317705756","volume":"39","author":"Y Shen","year":"2017","unstructured":"Shen Y et al (2017) A long non-coding RNA lncRNA-PE promotes invasion and epithelial\u2013mesenchymal transition in hepatocellular carcinoma through the miR-200a\/b-ZEB1 pathway. Tumor Biology 39(5):1010428317705756","journal-title":"Tumor Biology"},{"key":"10077_CR114","doi-asserted-by":"publisher","DOI":"10.20517\/2394-4722.2019.11","author":"AJ Gooding","year":"2019","unstructured":"Gooding AJ et al (2019) The IncRNA BORG: a novel inducer of TNBC metastasis, chemoresistance, and disease recurrence. J Cancer Metastasis Treat. https:\/\/doi.org\/10.20517\/2394-4722.2019.11","journal-title":"J Cancer Metastasis Treat"},{"issue":"12","key":"10077_CR115","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1038\/s41388-018-0586-4","volume":"38","author":"AJ Gooding","year":"2019","unstructured":"Gooding AJ et al (2019) The lncRNA BORG facilitates the survival and chemoresistance of triple-negative breast cancers. Oncogene 38(12):2020\u20132041","journal-title":"Oncogene"},{"issue":"1","key":"10077_CR116","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-017-12716-6","volume":"7","author":"AJ Gooding","year":"2017","unstructured":"Gooding AJ et al (2017) The lncRNA BORG drives breast cancer metastasis and disease recurrence. Sci Rep 7(1):1\u201318","journal-title":"Sci Rep"},{"issue":"1","key":"10077_CR117","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12943-017-0753-1","volume":"17","author":"H Liang","year":"2018","unstructured":"Liang H et al (2018) LncRNA PTAR promotes EMT and invasion-metastasis in serous ovarian cancer by competitively binding miR-101\u20133p to regulate ZEB1 expression. Mol Cancer 17(1):1\u201313","journal-title":"Mol Cancer"},{"issue":"3","key":"10077_CR118","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1111\/jgh.13206","volume":"31","author":"B Yue","year":"2016","unstructured":"Yue B et al (2016) LncRNA-ATB mediated E-cadherin repression promotes the progression of colon cancer and predicts poor prognosis. J Gastroenterol Hepatol 31(3):595\u2013603","journal-title":"J Gastroenterol Hepatol"},{"issue":"6","key":"10077_CR119","doi-asserted-by":"crossref","first-page":"3013","DOI":"10.1093\/nar\/gkz117","volume":"47","author":"D Qu","year":"2019","unstructured":"Qu D et al (2019) Long noncoding RNA MALAT1 releases epigenetic silencing of HIV-1 replication by displacing the polycomb repressive complex 2 from binding to the LTR promoter. Nucleic Acids Res 47(6):3013\u20133027","journal-title":"Nucleic Acids Res"},{"key":"10077_CR120","doi-asserted-by":"publisher","DOI":"10.3390\/cells8101178","author":"J-T Cheng","year":"2019","unstructured":"Cheng J-T et al (2019) Insights into biological role of LncRNAs in epithelial-mesenchymal transition. Cells. https:\/\/doi.org\/10.3390\/cells8101178","journal-title":"Cells"},{"issue":"12","key":"10077_CR121","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1261\/rna.053918.115","volume":"21","author":"C Davidovich","year":"2015","unstructured":"Davidovich C, Cech TR (2015) The recruitment of chromatin modifiers by long noncoding RNAs: lessons from PRC2. RNA 21(12):2007\u20132022","journal-title":"RNA"},{"issue":"4","key":"10077_CR122","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.molcel.2016.04.010","volume":"62","author":"S Kumar","year":"2016","unstructured":"Kumar S et al (2016) Activation of Mitofusin2 by Smad2-RIN1 complex during mitochondrial fusion. Mol Cell 62(4):520\u2013531","journal-title":"Mol Cell"},{"issue":"8","key":"10077_CR123","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1038\/s41388-019-1097-7","volume":"39","author":"YS Kim","year":"2020","unstructured":"Kim YS et al (2020) Context-dependent activation of SIRT3 is necessary for anchorage-independent survival and metastasis of ovarian cancer cells. Oncogene 39(8):1619\u20131633","journal-title":"Oncogene"},{"issue":"6958","key":"10077_CR124","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/nature02006","volume":"425","author":"R Derynck","year":"2003","unstructured":"Derynck R, Zhang YE (2003) Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature 425(6958):577\u2013584","journal-title":"Nature"},{"issue":"2","key":"10077_CR125","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s10911-011-9207-3","volume":"16","author":"JG Parvani","year":"2011","unstructured":"Parvani JG, Taylor MA, Schiemann WP (2011) Noncanonical TGF-\u03b2 signaling during mammary tumorigenesis. J Mammary Gland Biol Neoplasia 16(2):127\u2013146","journal-title":"J Mammary Gland Biol Neoplasia"},{"issue":"1","key":"10077_CR126","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1042\/BJ20121701","volume":"454","author":"SY Oh","year":"2013","unstructured":"Oh SY et al (2013) The type III TGFbeta receptor regulates filopodia formation via a Cdc42-mediated IRSp53-N-WASP interaction in epithelial cells. Biochem J 454(1):79\u201389","journal-title":"Biochem J"},{"issue":"20","key":"10077_CR127","doi-asserted-by":"crossref","first-page":"8221","DOI":"10.1073\/pnas.0812879106","volume":"106","author":"K Mythreye","year":"2009","unstructured":"Mythreye K, Blobe GC (2009) The type III TGF-beta receptor regulates epithelial and cancer cell migration through beta-arrestin2-mediated activation of Cdc42. Proc Natl Acad Sci U S A 106(20):8221\u20138226","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"15","key":"10077_CR128","doi-asserted-by":"crossref","first-page":"3193","DOI":"10.1242\/jcs.115.15.3193","volume":"115","author":"AV Bakin","year":"2002","unstructured":"Bakin AV et al (2002) p38 mitogen-activated protein kinase is required for TGFbeta-mediated fibroblastic transdifferentiation and cell migration. J Cell Sci 115(15):3193\u20133206","journal-title":"J Cell Sci"},{"key":"10077_CR129","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/2045-3701-1-42","volume":"1","author":"DA Chapnick","year":"2011","unstructured":"Chapnick DA et al (2011) Partners in crime: the TGF\u03b2 and MAPK pathways in cancer progression. Cell Biosci 1:42","journal-title":"Cell Biosci"},{"issue":"5","key":"10077_CR130","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/j.cellsig.2013.01.016","volume":"25","author":"Y Cha","year":"2013","unstructured":"Cha Y et al (2013) TCEA3 binds to TGF-beta receptor I and induces Smad-independent, JNK-dependent apoptosis in ovarian cancer cells. Cell Signal 25(5):1245\u20131251","journal-title":"Cell Signal"},{"issue":"17","key":"10077_CR131","doi-asserted-by":"crossref","first-page":"3957","DOI":"10.1038\/sj.emboj.7601818","volume":"26","author":"MK Lee","year":"2007","unstructured":"Lee MK et al (2007) TGF-beta activates Erk MAP kinase signalling through direct phosphorylation of ShcA. EMBO J 26(17):3957\u20133967","journal-title":"EMBO J"},{"issue":"8","key":"10077_CR132","doi-asserted-by":"crossref","first-page":"3752","DOI":"10.1158\/0008-5472.CAN-06-3851","volume":"67","author":"AJ Galliher","year":"2007","unstructured":"Galliher AJ, Schiemann WP (2007) Src phosphorylates Tyr284 in TGF-beta type II receptor and regulates TGF-beta stimulation of p38 MAPK during breast cancer cell proliferation and invasion. Cancer Res 67(8):3752\u20133758","journal-title":"Cancer Res"},{"issue":"1\u20132","key":"10077_CR133","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S1359-6101(99)00026-X","volume":"11","author":"KM Mulder","year":"2000","unstructured":"Mulder KM (2000) Role of Ras and Mapks in TGFbeta signaling. Cytokine Growth Factor Rev 11(1\u20132):23\u201335","journal-title":"Cytokine Growth Factor Rev"},{"issue":"5","key":"10077_CR134","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1593\/neo.04241","volume":"6","author":"L Xie","year":"2004","unstructured":"Xie L et al (2004) Activation of the Erk pathway is required for TGF-beta1-induced EMT in vitro. Neoplasia 6(5):603\u2013610","journal-title":"Neoplasia"},{"issue":"10","key":"10077_CR135","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1038\/ncb1780","volume":"10","author":"A Sorrentino","year":"2008","unstructured":"Sorrentino A et al (2008) The type I TGF-beta receptor engages TRAF6 to activate TAK1 in a receptor kinase-independent manner. Nat Cell Biol 10(10):1199\u20131207","journal-title":"Nat Cell Biol"},{"issue":"6","key":"10077_CR136","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/j.molcel.2008.09.002","volume":"31","author":"M Yamashita","year":"2008","unstructured":"Yamashita M et al (2008) TRAF6 mediates Smad-independent activation of JNK and p38 by TGF-beta. Mol Cell 31(6):918\u2013924","journal-title":"Mol Cell"},{"issue":"22","key":"10077_CR137","doi-asserted-by":"crossref","first-page":"5385","DOI":"10.1016\/j.febslet.2006.09.003","volume":"580","author":"JF Santiba\u00f1ez","year":"2006","unstructured":"Santiba\u00f1ez JF (2006) JNK mediates TGF-beta1-induced epithelial mesenchymal transdifferentiation of mouse transformed keratinocytes. FEBS Lett 580(22):5385\u20135391","journal-title":"FEBS Lett"},{"issue":"5","key":"10077_CR138","doi-asserted-by":"crossref","first-page":"6433","DOI":"10.18632\/oncotarget.23942","volume":"9","author":"S Dash","year":"2018","unstructured":"Dash S et al (2018) TGF-\u03b22-induced EMT is dampened by inhibition of autophagy and TNF-\u03b1 treatment. Oncotarget 9(5):6433\u20136449","journal-title":"Oncotarget"},{"issue":"1","key":"10077_CR139","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1186\/s13046-017-0628-8","volume":"36","author":"C Zhang","year":"2017","unstructured":"Zhang C et al (2017) TGF-\u03b22 initiates autophagy via Smad and non-Smad pathway to promote glioma cells invasion. J Exp Clin Cancer Res 36(1):162","journal-title":"J Exp Clin Cancer Res"},{"issue":"5715","key":"10077_CR140","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1126\/science.1105718","volume":"307","author":"B Ozdamar","year":"2005","unstructured":"Ozdamar B et al (2005) Regulation of the polarity protein Par6 by TGFbeta receptors controls epithelial cell plasticity. Science 307(5715):1603\u20131609","journal-title":"Science"},{"issue":"2","key":"10077_CR141","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/nrc.2015.18","volume":"16","author":"ED Fleuren","year":"2016","unstructured":"Fleuren ED et al (2016) The kinome\u2019 at large\u2019in cancer. Nature Rev Cancer 16(2):83","journal-title":"Nature Rev Cancer"},{"issue":"5","key":"10077_CR142","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1016\/j.celrep.2019.07.001","volume":"28","author":"LA Donehower","year":"2019","unstructured":"Donehower LA et al (2019) Integrated analysis of TP53 gene and pathway alterations in the cancer genome atlas. Cell Rep 28(5):1370\u20131384","journal-title":"Cell Rep"},{"issue":"20","key":"10077_CR143","doi-asserted-by":"crossref","first-page":"5806","DOI":"10.1158\/1078-0432.CCR-12-0857","volume":"18","author":"ZC Wang","year":"2012","unstructured":"Wang ZC et al (2012) Profiles of genomic instability in high-grade serous ovarian cancer predict treatment outcome. Clin Cancer Res 18(20):5806\u20135815","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10077_CR144","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.cels.2018.08.010","volume":"7","author":"A Korkut","year":"2018","unstructured":"Korkut A et al (2018) A pan-cancer analysis reveals high-frequency genetic alterations in mediators of signaling by the TGF-beta superfamily. Cell Syst 7(4):422\u2013437","journal-title":"Cell Syst"},{"key":"10077_CR145","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/2170606","author":"WJ Junhan Zhou","year":"2020","unstructured":"Junhan Zhou WJ, Huang W, Ye M, Zhu X (2020) Prognostic values of transforming growth factor-betasubtypes in ovarian cancer. BioMed Res Int. https:\/\/doi.org\/10.1155\/2020\/2170606","journal-title":"BioMed Res Int"},{"issue":"7","key":"10077_CR146","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1006\/cyto.1999.0632","volume":"12","author":"B Abendstein","year":"2000","unstructured":"Abendstein B et al (2000) Regulation of transforming growth factor-\u03b2 secretion by human peritoneal mesothelial and ovarian carcinoma cells. Cytokine 12(7):1115\u20131119","journal-title":"Cytokine"},{"key":"10077_CR147","doi-asserted-by":"crossref","first-page":"287","DOI":"10.2147\/IJWH.S197604","volume":"11","author":"Z Momenimovahed","year":"2019","unstructured":"Momenimovahed Z et al (2019) Ovarian cancer in the world: epidemiology and risk factors. Int J Womens Health 11:287\u2013299","journal-title":"Int J Womens Health"},{"issue":"3","key":"10077_CR148","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1097\/PAS.0b013e3181cf3d79","volume":"34","author":"RJ Kurman","year":"2010","unstructured":"Kurman RJ, Shih Ie M (2010) The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am J Surg Pathol 34(3):433\u2013443","journal-title":"Am J Surg Pathol"},{"issue":"8","key":"10077_CR149","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1038\/s41416-020-0763-4","volume":"122","author":"T Masoodi","year":"2020","unstructured":"Masoodi T et al (2020) Genetic heterogeneity and evolutionary history of high-grade ovarian carcinoma and matched distant metastases. British J Cancer 122(8):1219\u20131230","journal-title":"British J Cancer"},{"issue":"1","key":"10077_CR150","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/ncomms12645","volume":"7","author":"F Coscia","year":"2016","unstructured":"Coscia F et al (2016) Integrative proteomic profiling of ovarian cancer cell lines reveals precursor cell associated proteins and functional status. Nature Commun 7(1):1\u201314","journal-title":"Nature Commun"},{"issue":"1","key":"10077_CR151","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1002\/path.2696","volume":"221","author":"AA Ahmed","year":"2010","unstructured":"Ahmed AA et al (2010) Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary. J Pathol 221(1):49\u201356","journal-title":"J Pathol"},{"issue":"7353","key":"10077_CR152","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/nature10166","volume":"474","author":"CGAR Network","year":"2011","unstructured":"Network CGAR (2011) Integrated genomic analyses of ovarian carcinoma. Nature 474(7353):609","journal-title":"Nature"},{"key":"10077_CR153","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/dju249","author":"GE Konecny","year":"2014","unstructured":"Konecny GE et al (2014) Prognostic and therapeutic relevance of molecular subtypes in high-grade serous ovarian cancer. JNCI. https:\/\/doi.org\/10.1093\/jnci\/dju249","journal-title":"JNCI"},{"issue":"19","key":"10077_CR154","doi-asserted-by":"crossref","first-page":"17261","DOI":"10.18632\/oncotarget.3746","volume":"6","author":"K Auer","year":"2015","unstructured":"Auer K et al (2015) Peritoneal tumor spread in serous ovarian cancer-epithelial mesenchymal status and outcome. Oncotarget 6(19):17261\u201317275","journal-title":"Oncotarget"},{"issue":"3","key":"10077_CR155","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1086\/318787","volume":"68","author":"HA Risch","year":"2001","unstructured":"Risch HA et al (2001) Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am J Hum Genet 68(3):700\u2013710","journal-title":"Am J Hum Genet"},{"issue":"8","key":"10077_CR156","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1016\/j.molonc.2015.05.002","volume":"9","author":"D Li","year":"2015","unstructured":"Li D et al (2015) BRCA1 regulates transforming growth factor-\u03b2 (TGF-\u03b21) signaling through Gadd45a by enhancing the protein stability of Smad4. Mol Oncol 9(8):1655\u20131666","journal-title":"Mol Oncol"},{"issue":"2","key":"10077_CR157","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1097\/01.pas.0000213335.40358.47","volume":"31","author":"DW Kindelberger","year":"2007","unstructured":"Kindelberger DW et al (2007) Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: evidence for a causal relationship. Am J Surg Pathol 31(2):161\u2013169","journal-title":"Am J Surg Pathol"},{"issue":"10","key":"10077_CR158","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1097\/PAS.0b013e3181ef7b16","volume":"34","author":"CG Przybycin","year":"2010","unstructured":"Przybycin CG et al (2010) Are all pelvic (nonuterine) serous carcinomas of tubal origin? Am J Surg Pathol 34(10):1407\u20131416","journal-title":"Am J Surg Pathol"},{"issue":"6","key":"10077_CR159","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.ccr.2013.10.013","volume":"24","author":"R Perets","year":"2013","unstructured":"Perets R et al (2013) Transformation of the fallopian tube secretory epithelium leads to high-grade serous ovarian cancer in Brca;Tp53;Pten models. Cancer Cell 24(6):751\u2013765","journal-title":"Cancer Cell"},{"issue":"1","key":"10077_CR160","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1038\/s41467-017-00962-1","volume":"8","author":"SI Labidi-Galy","year":"2017","unstructured":"Labidi-Galy SI et al (2017) High grade serous ovarian carcinomas originate in the fallopian tube. Nature Commun 8(1):1093","journal-title":"Nature Commun"},{"issue":"2","key":"10077_CR161","first-page":"255","volume":"22","author":"N Auersperg","year":"2001","unstructured":"Auersperg N et al (2001) Ovarian surface epithelium: biology, endocrinology, and pathology. Endocr Rev 22(2):255\u2013288","journal-title":"Endocr Rev"},{"key":"10077_CR162","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.trsl.2016.03.016","volume":"175","author":"LG Coffman","year":"2016","unstructured":"Coffman LG et al (2016) New models of hematogenous ovarian cancer metastasis demonstrate preferential spread to the ovary and a requirement for the ovary for abdominal dissemination. Transl Res 175:92-102.e2","journal-title":"Transl Res"},{"issue":"4","key":"10077_CR163","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.matbio.2004.05.008","volume":"23","author":"HF Irving-Rodgers","year":"2004","unstructured":"Irving-Rodgers HF, Harland ML, Rodgers RJ (2004) A novel basal lamina matrix of the stratified epithelium of the ovarian follicle. Matrix Biol 23(4):207\u2013217","journal-title":"Matrix Biol"},{"issue":"10","key":"10077_CR164","doi-asserted-by":"crossref","first-page":"e46858","DOI":"10.1371\/journal.pone.0046858","volume":"7","author":"A Latifi","year":"2012","unstructured":"Latifi A et al (2012) Isolation and characterization of tumor cells from the ascites of ovarian cancer patients: molecular phenotype of chemoresistant ovarian tumors. PLoS ONE 7(10):e46858","journal-title":"PLoS ONE"},{"issue":"6","key":"10077_CR165","doi-asserted-by":"crossref","first-page":"2611","DOI":"10.1172\/JCI69815","volume":"124","author":"RA Davidowitz","year":"2014","unstructured":"Davidowitz RA et al (2014) Mesenchymal gene program\u2013expressing ovarian cancer spheroids exhibit enhanced mesothelial clearance. J Clin Invest 124(6):2611\u20132625","journal-title":"J Clin Invest"},{"issue":"11","key":"10077_CR166","doi-asserted-by":"crossref","first-page":"e915","DOI":"10.1038\/cddis.2013.442","volume":"4","author":"RYJ Huang","year":"2013","unstructured":"Huang RYJ et al (2013) An EMT spectrum defines an anoikis-resistant and spheroidogenic intermediate mesenchymal state that is sensitive to e-cadherin restoration by a src-kinase inhibitor, saracatinib (AZD0530). Cell Death Disease 4(11):e915","journal-title":"Cell Death Disease"},{"issue":"2","key":"10077_CR167","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/sj.bjc.6604115","volume":"98","author":"K Blechschmidt","year":"2008","unstructured":"Blechschmidt K et al (2008) The E-cadherin repressor Snail is associated with lower overall survival of ovarian cancer patients. British J Cancer 98(2):489\u2013495","journal-title":"British J Cancer"},{"issue":"5","key":"10077_CR168","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.humpath.2008.10.013","volume":"40","author":"HS Shim","year":"2009","unstructured":"Shim HS, Yoon BS, Cho NH (2009) Prognostic significance of paired epithelial cell adhesion molecule and E-cadherin in ovarian serous carcinoma. Human Pathol 40(5):693\u2013698","journal-title":"Human Pathol"},{"issue":"1","key":"10077_CR169","doi-asserted-by":"crossref","first-page":"3231","DOI":"10.1038\/s41467-020-17030-w","volume":"11","author":"M Knarr","year":"2020","unstructured":"Knarr M et al (2020) miR-181a initiates and perpetuates oncogenic transformation through the regulation of innate immune signaling. Nature Commun 11(1):3231","journal-title":"Nature Commun"},{"issue":"7689","key":"10077_CR170","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/nature25432","volume":"553","author":"SF Bakhoum","year":"2018","unstructured":"Bakhoum SF et al (2018) Chromosomal instability drives metastasis through a cytosolic DNA response. Nature 553(7689):467\u2013472","journal-title":"Nature"},{"issue":"3","key":"10077_CR171","doi-asserted-by":"crossref","first-page":"933","DOI":"10.3892\/ijo.2015.2816","volume":"46","author":"P Papageorgis","year":"2015","unstructured":"Papageorgis P, Stylianopoulos T (2015) Role of TGF\u03b2 in regulation of the tumor microenvironment and drug delivery. Int J Oncol 46(3):933\u2013943","journal-title":"Int J Oncol"},{"issue":"24","key":"10077_CR172","doi-asserted-by":"crossref","first-page":"7106","DOI":"10.1158\/0008-5472.CAN-16-1456","volume":"76","author":"A Metelli","year":"2016","unstructured":"Metelli A et al (2016) Surface expression of TGF\u03b2 docking receptor GARP promotes oncogenesis and immune tolerance in breast cancer. Cancer Res 76(24):7106\u20137117","journal-title":"Cancer Res"},{"issue":"2","key":"10077_CR173","doi-asserted-by":"crossref","first-page":"e56664","DOI":"10.1371\/journal.pone.0056664","volume":"8","author":"H Wang","year":"2013","unstructured":"Wang H et al (2013) Epithelial\u2013mesenchymal transition (EMT) induced by TNF-\u03b1 requires AKT\/GSK-3\u03b2-mediated stabilization of snail in colorectal cancer. PLoS ONE 8(2):e56664","journal-title":"PLoS ONE"},{"issue":"1","key":"10077_CR174","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.canlet.2015.01.010","volume":"359","author":"JV Joseph","year":"2015","unstructured":"Joseph JV et al (2015) Hypoxia enhances migration and invasion in glioblastoma by promoting a mesenchymal shift mediated by the HIF1\u03b1\u2013ZEB1 axis. Cancer Lett 359(1):107\u2013116","journal-title":"Cancer Lett"},{"issue":"7","key":"10077_CR175","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1016\/j.cellsig.2014.02.017","volume":"26","author":"JM Overstreet","year":"2014","unstructured":"Overstreet JM et al (2014) Redox control of p53 in the transcriptional regulation of TGF-\u03b21 target genes through SMAD cooperativity. Cell Signal 26(7):1427\u20131436","journal-title":"Cell Signal"},{"issue":"1","key":"10077_CR176","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1165\/rcmb.2013-0519OC","volume":"52","author":"OA Jaffer","year":"2015","unstructured":"Jaffer OA et al (2015) Mitochondrial-targeted antioxidant therapy decreases transforming growth factor-\u03b2\u2013mediated collagen production in a murine asthma model. Am J Respir Cell Mol Biol 52(1):106\u2013115","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"8","key":"10077_CR177","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1038\/labinvest.3700109","volume":"84","author":"DA Pociask","year":"2004","unstructured":"Pociask DA, Sime PJ, Brody AR (2004) Asbestos-derived reactive oxygen species activate TGF-\u03b2 1. Lab Invest 84(8):1013\u20131023","journal-title":"Lab Invest"},{"issue":"3","key":"10077_CR178","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s00018-017-2663-1","volume":"75","author":"J Miku\u0142a-Pietrasik","year":"2018","unstructured":"Miku\u0142a-Pietrasik J et al (2018) The peritoneal \u201csoil\u201d for a cancerous \u201cseed\u201d: a comprehensive review of the pathogenesis of intraperitoneal cancer metastases. Cell Mol Life Sci 75(3):509\u2013525","journal-title":"Cell Mol Life Sci"},{"issue":"1","key":"10077_CR179","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1158\/1078-0432.113.11.1","volume":"11","author":"E Wang","year":"2005","unstructured":"Wang E et al (2005) Peritoneal and subperitoneal stroma may facilitate regional spread of ovarian cancer. Clin Cancer Res 11(1):113","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10077_CR180","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.ygyno.2003.12.034","volume":"93","author":"KM Burleson","year":"2004","unstructured":"Burleson KM et al (2004) Ovarian carcinoma ascites spheroids adhere to extracellular matrix components and mesothelial cell monolayers. Gynecol Oncol 93(1):170\u2013181","journal-title":"Gynecol Oncol"},{"issue":"10","key":"10077_CR181","doi-asserted-by":"crossref","first-page":"4614","DOI":"10.1172\/JCI74778","volume":"124","author":"HA Kenny","year":"2014","unstructured":"Kenny HA et al (2014) Mesothelial cells promote early ovarian cancer metastasis through fibronectin secretion. J Clin Invest 124(10):4614\u20134628","journal-title":"J Clin Invest"},{"issue":"1","key":"10077_CR182","doi-asserted-by":"crossref","first-page":"14323","DOI":"10.1038\/s41598-018-32737-z","volume":"8","author":"P He","year":"2018","unstructured":"He P, Qiu K, Jia Y (2018) Modeling of mesenchymal hybrid epithelial state and phenotypic transitions in EMT and MET processes of cancer cells. Sci Rep 8(1):14323","journal-title":"Sci Rep"},{"key":"10077_CR183","doi-asserted-by":"crossref","first-page":"473134","DOI":"10.1155\/2014\/473134","volume":"2014","author":"M L\u00f3pez-Cabrera","year":"2014","unstructured":"L\u00f3pez-Cabrera M (2014) Mesenchymal conversion of mesothelial cells is a key event in the pathophysiology of the peritoneum during peritoneal dialysis. Adv Med 2014:473134","journal-title":"Adv Med"},{"issue":"8","key":"10077_CR184","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1038\/s41419-020-02822-1","volume":"11","author":"R Strippoli","year":"2020","unstructured":"Strippoli R et al (2020) Caveolin1 and YAP drive mechanically induced mesothelial to mesenchymal transition and fibrosis. Cell Death Dis 11(8):647","journal-title":"Cell Death Dis"},{"issue":"9","key":"10077_CR185","doi-asserted-by":"crossref","first-page":"e106773","DOI":"10.1371\/journal.pone.0106773","volume":"9","author":"VJ Young","year":"2014","unstructured":"Young VJ et al (2014) The peritoneum is both a source and target of TGF-\u03b2 in women with endometriosis. PLoS ONE 9(9):e106773","journal-title":"PLoS ONE"},{"issue":"4","key":"10077_CR186","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1002\/path.4281","volume":"231","author":"P Sandoval","year":"2013","unstructured":"Sandoval P et al (2013) Carcinoma-associated fibroblasts derive from mesothelial cells via mesothelial-to-mesenchymal transition in peritoneal metastasis. J Pathol 231(4):517\u2013531","journal-title":"J Pathol"},{"issue":"3","key":"10077_CR187","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1084\/jem.20180765","volume":"216","author":"Q Gao","year":"2019","unstructured":"Gao Q et al (2019) Heterotypic CAF-tumor spheroids promote early peritoneal metastatis of ovarian cancer. J Exp Med 216(3):688\u2013703","journal-title":"J Exp Med"},{"issue":"7","key":"10077_CR188","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1038\/sj.bjc.6601635","volume":"90","author":"RM Heath","year":"2004","unstructured":"Heath RM et al (2004) Tumour-induced apoptosis in human mesothelial cells: a mechanism of peritoneal invasion by Fas Ligand\/Fas interaction. British J Cancer 90(7):1437\u20131442","journal-title":"British J Cancer"},{"issue":"2","key":"10077_CR189","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1158\/2159-8274.CD-11-0010","volume":"1","author":"MP Iwanicki","year":"2011","unstructured":"Iwanicki MP et al (2011) Ovarian cancer spheroids use myosin-generated force to clear the mesothelium. Cancer Discov 1(2):144","journal-title":"Cancer Discov"},{"issue":"1","key":"10077_CR190","doi-asserted-by":"crossref","first-page":"45523","DOI":"10.1038\/srep45523","volume":"7","author":"Y Liu","year":"2017","unstructured":"Liu Y et al (2017) YAP modulates TGF-\u03b21-induced simultaneous apoptosis and EMT through upregulation of the EGF receptor. Sci Rep 7(1):45523","journal-title":"Sci Rep"},{"issue":"55","key":"10077_CR191","doi-asserted-by":"crossref","first-page":"7235","DOI":"10.1038\/sj.onc.1209712","volume":"25","author":"Y Yang","year":"2006","unstructured":"Yang Y et al (2006) Transforming growth factor-beta1 induces epithelial-to-mesenchymal transition and apoptosis via a cell cycle-dependent mechanism. Oncogene 25(55):7235\u20137244","journal-title":"Oncogene"},{"issue":"1","key":"10077_CR192","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1186\/s12885-015-1511-7","volume":"15","author":"D Lane","year":"2015","unstructured":"Lane D et al (2015) Inflammation-regulating factors in ascites as predictive biomarkers of drug resistance and progression-free survival in serous epithelial ovarian cancers. BMC Cancer 15(1):492","journal-title":"BMC Cancer"},{"key":"10077_CR193","first-page":"367103","volume":"2014","author":"T Feigenberg","year":"2014","unstructured":"Feigenberg T et al (2014) Molecular profiling and clinical outcome of high-grade serous ovarian cancer presenting with low- versus high-volume ascites. Biomed Res Int 2014:367103","journal-title":"Biomed Res Int"},{"issue":"1","key":"10077_CR194","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41416-020-0875-x","volume":"123","author":"CE Ford","year":"2020","unstructured":"Ford CE et al (2020) The untapped potential of ascites in ovarian cancer research and treatment. British J Cancer 123(1):9\u201316","journal-title":"British J Cancer"},{"key":"10077_CR195","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.ejca.2019.05.029","volume":"117","author":"CK Lee","year":"2019","unstructured":"Lee CK et al (2019) Development and validation of a prognostic nomogram for overall survival in patients with platinum-resistant ovarian cancer treated with chemotherapy. Eur J Cancer 117:99\u2013106","journal-title":"Eur J Cancer"},{"issue":"6","key":"10077_CR196","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/j.jamcollsurg.2004.01.035","volume":"198","author":"RA Adam","year":"2004","unstructured":"Adam RA, Adam YG (2004) Malignant ascites: past, present, and future. J Am Coll Surg 198(6):999\u20131011","journal-title":"J Am Coll Surg"},{"issue":"11","key":"10077_CR197","first-page":"2631","volume":"53","author":"JA Nagy","year":"1993","unstructured":"Nagy JA et al (1993) Pathogenesis of malignant ascites formation: initiating events that lead to fluid accumulation. Cancer Res 53(11):2631\u20132643","journal-title":"Cancer Res"},{"issue":"6","key":"10077_CR198","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1158\/1078-0432.CCR-10-2429","volume":"17","author":"S Liao","year":"2011","unstructured":"Liao S et al (2011) TGF-beta blockade controls ascites by preventing abnormalization of lymphatic vessels in orthotopic human ovarian carcinoma models. Clin Cancer Res 17(6):1415\u20131424","journal-title":"Clin Cancer Res"},{"issue":"8","key":"10077_CR199","first-page":"804","volume":"108","author":"AD Santin","year":"2001","unstructured":"Santin AD et al (2001) Increased levels of interleukin-10 and transforming growth factor-beta in the plasma and ascitic fluid of patients with advanced ovarian cancer. BJOG 108(8):804\u2013808","journal-title":"BJOG"},{"issue":"31","key":"10077_CR200","doi-asserted-by":"crossref","first-page":"51008","DOI":"10.18632\/oncotarget.16846","volume":"8","author":"L Yang","year":"2017","unstructured":"Yang L et al (2017) Ascites promotes cell migration through the repression of miR-125b in ovarian cancer. Oncotarget 8(31):51008\u201351015","journal-title":"Oncotarget"},{"issue":"2","key":"10077_CR201","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/0304-3835(92)90186-Y","volume":"62","author":"B Sheid","year":"1992","unstructured":"Sheid B (1992) Angiogenic effects of macrophages isolated from ascitic fluid aspirated from women with advanced ovarian cancer. Cancer Lett 62(2):153\u2013158","journal-title":"Cancer Lett"},{"issue":"21","key":"10077_CR202","doi-asserted-by":"crossref","first-page":"4227","DOI":"10.1038\/s41388-020-1288-2","volume":"39","author":"T Kan","year":"2020","unstructured":"Kan T et al (2020) Single-cell EMT-related transcriptional analysis revealed intra-cluster heterogeneity of tumor cell clusters in epithelial ovarian cancer ascites. Oncogene 39(21):4227\u20134240","journal-title":"Oncogene"},{"issue":"5","key":"10077_CR203","doi-asserted-by":"crossref","first-page":"662","DOI":"10.3390\/cancers11050662","volume":"11","author":"M Paku\u0142a","year":"2019","unstructured":"Paku\u0142a M et al (2019) A unique pattern of mesothelial-mesenchymal transition induced in the normal peritoneal mesothelium by high-grade serous ovarian cancer. Cancers 11(5):662","journal-title":"Cancers"},{"key":"10077_CR204","first-page":"3481","volume":"12","author":"P Paoli","year":"1833","unstructured":"Paoli P, Giannoni E (1833) Anoikis molecular pathways and its role in cancer progression. Biochimica et Biophysica Acta (BBA) Mol Cell Res 12:3481\u20133498","journal-title":"Biochimica et Biophysica Acta (BBA) Mol Cell Res"},{"issue":"1","key":"10077_CR205","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/s12943-017-0659-y","volume":"16","author":"X Li","year":"2017","unstructured":"Li X, Wang X (2017) The emerging roles and therapeutic potential of exosomes in epithelial ovarian cancer. Mol Cancer 16(1):92","journal-title":"Mol Cancer"},{"issue":"23","key":"10077_CR206","doi-asserted-by":"crossref","first-page":"9621","DOI":"10.1158\/0008-5472.CAN-10-1722","volume":"70","author":"J Webber","year":"2010","unstructured":"Webber J et al (2010) Cancer exosomes trigger fibroblast to myofibroblast differentiation. Cancer Res 70(23):9621\u20139630","journal-title":"Cancer Res"},{"issue":"1","key":"10077_CR207","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s12943-019-0991-5","volume":"18","author":"L Mashouri","year":"2019","unstructured":"Mashouri L et al (2019) Exosomes: composition, biogenesis, and mechanisms in cancer metastasis and drug resistance. Mol Cancer 18(1):75","journal-title":"Mol Cancer"},{"issue":"10","key":"10077_CR208","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1016\/j.celrep.2019.02.023","volume":"26","author":"L Cornell","year":"2019","unstructured":"Cornell L et al (2019) MicroRNA-mediated suppression of the TGF-\u03b2 pathway confers transmissible and reversible CDK4\/6 inhibitor resistance. Cell Rep 26(10):2667\u201380.e7","journal-title":"Cell Rep"},{"issue":"19","key":"10077_CR209","doi-asserted-by":"crossref","first-page":"7045","DOI":"10.1158\/0008-5472.CAN-04-1800","volume":"64","author":"LE Graves","year":"2004","unstructured":"Graves LE et al (2004) Proinvasive properties of ovarian cancer ascites-derived membrane vesicles. Cancer Res 64(19):7045\u20137049","journal-title":"Cancer Res"},{"issue":"10","key":"10077_CR210","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1111\/febs.12148","volume":"280","author":"T Neill","year":"2013","unstructured":"Neill T et al (2013) Decorin induces rapid secretion of thrombospondin-1 in basal breast carcinoma cells via inhibition of Ras homolog gene family, member A\/Rho-associated coiled-coil containing protein kinase 1. FEBS J 280(10):2353\u20132368","journal-title":"FEBS J"},{"issue":"2","key":"10077_CR211","first-page":"520","volume":"146","author":"S Yung","year":"1995","unstructured":"Yung S et al (1995) Source of peritoneal proteoglycans. Human peritoneal mesothelial cells synthesize and secrete mainly small dermatan sulfate proteoglycans. Am J Pathol 146(2):520\u2013529","journal-title":"Am J Pathol"},{"issue":"11","key":"10077_CR212","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1038\/nm.2492","volume":"17","author":"KM Nieman","year":"2011","unstructured":"Nieman KM et al (2011) Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth. Nature Med 17(11):1498","journal-title":"Nature Med"},{"issue":"4","key":"10077_CR213","doi-asserted-by":"crossref","first-page":"e20191869","DOI":"10.1084\/jem.20191869","volume":"217","author":"A Etzerodt","year":"2020","unstructured":"Etzerodt A et al (2020) Tissue-resident macrophages in omentum promote metastatic spread of ovarian cancer. J Exp Med 217(4):e20191869","journal-title":"J Exp Med"},{"issue":"4","key":"10077_CR214","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1097\/IGC.0000000000000412","volume":"25","author":"L McNally","year":"2015","unstructured":"McNally L et al (2015) Does omentectomy in epithelial ovarian cancer affect survival? An analysis of the surveillance, epidemiology, and end results database. Int J Gynecol Cancer 25(4):607\u2013615","journal-title":"Int J Gynecol Cancer"},{"issue":"16","key":"10077_CR215","doi-asserted-by":"crossref","first-page":"2885","DOI":"10.1038\/s41388-018-0637-x","volume":"38","author":"T Motohara","year":"2019","unstructured":"Motohara T et al (2019) An evolving story of the metastatic voyage of ovarian cancer cells: cellular and molecular orchestration of the adipose-rich metastatic microenvironment. Oncogene 38(16):2885\u20132898","journal-title":"Oncogene"},{"issue":"2","key":"10077_CR216","first-page":"90","volume":"26","author":"M Shimotsuma","year":"1993","unstructured":"Shimotsuma M et al (1993) Morpho-physiological function and role of omental milky spots as omentum-associated lymphoid tissue (OALT) in the peritoneal cavity. Lymphology 26(2):90\u2013101","journal-title":"Lymphology"},{"issue":"1","key":"10077_CR217","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1093\/carcin\/bgr230","volume":"33","author":"J Cai","year":"2012","unstructured":"Cai J et al (2012) Fibroblasts in omentum activated by tumor cells promote ovarian cancer growth, adhesion and invasiveness. Carcinogenesis 33(1):20\u201329","journal-title":"Carcinogenesis"},{"issue":"3","key":"10077_CR218","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1158\/1078-0432.CCR-13-1256","volume":"20","author":"DJ Cheon","year":"2014","unstructured":"Cheon DJ et al (2014) A collagen-remodeling gene signature regulated by TGF-\u03b2 signaling is associated with metastasis and poor survival in serous ovarian cancer. Clin Cancer Res 20(3):711\u2013723","journal-title":"Clin Cancer Res"},{"key":"10077_CR219","doi-asserted-by":"crossref","first-page":"e59442","DOI":"10.7554\/eLife.59442","volume":"9","author":"YL Huang","year":"2020","unstructured":"Huang YL et al (2020) Collagen-rich omentum is a premetastatic niche for integrin \u03b12-mediated peritoneal metastasis. Elife 9:e59442","journal-title":"Elife"},{"issue":"7","key":"10077_CR220","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.it.2017.03.002","volume":"38","author":"S Meza-Perez","year":"2017","unstructured":"Meza-Perez S, Randall TD (2017) Immunological functions of the omentum. Trends Immunol 38(7):526\u2013536","journal-title":"Trends Immunol"},{"issue":"1","key":"10077_CR221","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.imbio.2015.11.016","volume":"222","author":"A Gratchev","year":"2017","unstructured":"Gratchev A (2017) TGF-beta signalling in tumour associated macrophages. Immunobiology 222(1):75\u201381","journal-title":"Immunobiology"},{"issue":"8","key":"10077_CR222","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1158\/1541-7786.MCR-12-0160","volume":"10","author":"M-Y Ho","year":"2012","unstructured":"Ho M-Y et al (2012) TNF-\u03b1 induces epithelial\u2013mesenchymal transition of renal cell carcinoma cells via a GSK3\u03b2-dependent mechanism. Mol Cancer Res 10(8):1109\u20131119","journal-title":"Mol Cancer Res"},{"issue":"2","key":"10077_CR223","doi-asserted-by":"crossref","first-page":"587","DOI":"10.3892\/ijo.2014.2761","volume":"46","author":"X-T Fu","year":"2015","unstructured":"Fu X-T et al (2015) Macrophage-secreted IL-8 induces epithelial-mesenchymal transition in hepatocellular carcinoma cells by activating the JAK2\/STAT3\/Snail pathway. Int J Oncol 46(2):587\u2013596","journal-title":"Int J Oncol"},{"key":"10077_CR224","first-page":"1533","volume":"10","author":"KM Nieman","year":"1831","unstructured":"Nieman KM et al (1831) (2013) Adipose tissue and adipocytes support tumorigenesis and metastasis. Biochimica et Biophysica Acta (BBA) Mol Cell Biol Lipids 10:1533\u20131541","journal-title":"Biochimica et Biophysica Acta (BBA) Mol Cell Biol Lipids"},{"issue":"12","key":"10077_CR225","doi-asserted-by":"crossref","first-page":"3280","DOI":"10.1158\/1078-0432.CCR-14-0445","volume":"20","author":"SL Tucker","year":"2014","unstructured":"Tucker SL et al (2014) Molecular biomarkers of residual disease after surgical debulking of high-grade serous ovarian cancer. Clin Cancer Res 20(12):3280\u20133288","journal-title":"Clin Cancer Res"},{"key":"10077_CR226","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.mce.2017.09.005","volume":"461","author":"J Jin","year":"2018","unstructured":"Jin J et al (2018) Fatty acid binding protein 4 promotes epithelial-mesenchymal transition in cervical squamous cell carcinoma through AKT\/GSK3\u03b2\/Snail signaling pathway. Mol Cell Endocrinol 461:155\u2013164","journal-title":"Mol Cell Endocrinol"},{"issue":"7","key":"10077_CR227","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1158\/0008-5472.CAN-10-3323","volume":"71","author":"B Dirat","year":"2011","unstructured":"Dirat B et al (2011) Cancer-associated adipocytes exhibit an activated phenotype and contribute to breast cancer invasion. Cancer Res 71(7):2455\u20132465","journal-title":"Cancer Res"},{"issue":"6","key":"10077_CR228","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1002\/emmm.201202006","volume":"5","author":"J Park","year":"2013","unstructured":"Park J, Morley TS, Scherer PE (2013) Inhibition of endotrophin, a cleavage product of collagen VI, confers cisplatin sensitivity to tumours. EMBO Mol Med 5(6):935\u2013948","journal-title":"EMBO Mol Med"},{"issue":"21","key":"10077_CR229","doi-asserted-by":"crossref","first-page":"5471","DOI":"10.1158\/0008-5472.CAN-19-1242","volume":"79","author":"D Ishay-Ronen","year":"2019","unstructured":"Ishay-Ronen D, Christofori G (2019) Targeting cancer cell metastasis by converting cancer cells into fat. Cancer Res 79(21):5471","journal-title":"Cancer Res"},{"issue":"8","key":"10077_CR230","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/S1470-2045(14)70228-1","volume":"15","author":"J Ledermann","year":"2014","unstructured":"Ledermann J et al (2014) Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol 15(8):852\u2013861","journal-title":"Lancet Oncol"},{"key":"10077_CR231","doi-asserted-by":"crossref","unstructured":"Bookman M, et al. (2017) Harmonising clinical trials within the gynecologic cancer intergroup: consensus and unmet needs from the Fifth Ovarian Cancer Consensus Conference. Ann Oncol 28(suppl_8):viii30-viii5","DOI":"10.1093\/annonc\/mdx449"},{"issue":"34","key":"10077_CR232","doi-asserted-by":"crossref","first-page":"55771","DOI":"10.18632\/oncotarget.9908","volume":"7","author":"J Deng","year":"2016","unstructured":"Deng J et al (2016) Targeting epithelial-mesenchymal transition and cancer stem cells for chemoresistant ovarian cancer. Oncotarget 7(34):55771","journal-title":"Oncotarget"},{"issue":"3","key":"10077_CR233","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1158\/1078-0432.CCR-11-2188","volume":"18","author":"AD Steg","year":"2012","unstructured":"Steg AD et al (2012) Stem cell pathways contribute to clinical chemoresistance in ovarian cancer. Clin Cancer Res 18(3):869\u2013881","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10077_CR234","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1002\/path.5222","volume":"247","author":"AG Smith","year":"2019","unstructured":"Smith AG, Macleod KF (2019) Autophagy, cancer stem cells and drug resistance. J Pathol 247(5):708\u2013718","journal-title":"J Pathol"},{"key":"10077_CR235","doi-asserted-by":"publisher","DOI":"10.1111\/cpr.12411","author":"PP Naik","year":"2018","unstructured":"Naik PP et al (2018) Autophagy regulates cisplatin-induced stemness and chemoresistance via the upregulation of CD44, ABCB1 and ADAM17 in oral squamous cell carcinoma. Cell Prolif. https:\/\/doi.org\/10.1111\/cpr.12411","journal-title":"Cell Prolif"},{"issue":"24","key":"10077_CR236","doi-asserted-by":"crossref","first-page":"3589","DOI":"10.1080\/15384101.2019.1693120","volume":"18","author":"E Bhagyaraj","year":"2019","unstructured":"Bhagyaraj E et al (2019) TGF-\u03b2 induced chemoresistance in liver cancer is modulated by xenobiotic nuclear receptor PXR. Cell Cycle 18(24):3589\u20133602","journal-title":"Cell Cycle"},{"issue":"14","key":"10077_CR237","doi-asserted-by":"crossref","first-page":"4411","DOI":"10.1073\/pnas.1421365112","volume":"112","author":"AK Srivastava","year":"2015","unstructured":"Srivastava AK et al (2015) Enhanced expression of DNA polymerase eta contributes to cisplatin resistance of ovarian cancer stem cells. Proc Natl Acad Sci USA 112(14):4411\u20134416","journal-title":"Proc Natl Acad Sci USA"},{"issue":"7","key":"10077_CR238","doi-asserted-by":"crossref","first-page":"e179","DOI":"10.1038\/cddis.2011.61","volume":"2","author":"M Saxena","year":"2011","unstructured":"Saxena M et al (2011) Transcription factors that mediate epithelial-mesenchymal transition lead to multidrug resistance by upregulating ABC transporters. Cell Death Dis 2(7):e179","journal-title":"Cell Death Dis"},{"issue":"1","key":"10077_CR239","doi-asserted-by":"crossref","first-page":"8704","DOI":"10.1038\/s41598-018-27021-z","volume":"8","author":"N Hojo","year":"2018","unstructured":"Hojo N et al (2018) Snail knockdown reverses stemness and inhibits tumour growth in ovarian cancer. Sci Rep 8(1):8704","journal-title":"Sci Rep"},{"issue":"9","key":"10077_CR240","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1002\/stem.154","volume":"27","author":"NK Kurrey","year":"2009","unstructured":"Kurrey NK et al (2009) Snail and slug mediate radioresistance and chemoresistance by antagonizing p53-mediated apoptosis and acquiring a stem-like phenotype in ovarian cancer cells. Stem Cells 27(9):2059\u20132068","journal-title":"Stem Cells"},{"issue":"7","key":"10077_CR241","doi-asserted-by":"crossref","first-page":"5775","DOI":"10.1002\/jcb.26753","volume":"119","author":"T Mitra","year":"2018","unstructured":"Mitra T et al (2018) Stemness and chemoresistance are imparted to the OC cells through TGF\u03b21 driven EMT. J Cell Biochem 119(7):5775\u20135787","journal-title":"J Cell Biochem"},{"issue":"5","key":"10077_CR242","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/j.cell.2012.10.035","volume":"151","author":"S Huang","year":"2012","unstructured":"Huang S et al (2012) MED12 controls the response to multiple cancer drugs through regulation of TGF-\u03b2 receptor signaling. Cell 151(5):937\u2013950","journal-title":"Cell"},{"issue":"9","key":"10077_CR243","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.tips.2014.06.006","volume":"35","author":"FM Davis","year":"2014","unstructured":"Davis FM et al (2014) Targeting EMT in cancer: opportunities for pharmacological intervention. Trends Pharmacol Sci 35(9):479\u2013488","journal-title":"Trends Pharmacol Sci"},{"issue":"2","key":"10077_CR244","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.ccr.2012.12.020","volume":"23","author":"D Yang","year":"2013","unstructured":"Yang D et al (2013) Integrated analyses identify a master microrna regulatory network for the mesenchymal subtype in serous ovarian cancer. Cancer Cell 23(2):186\u2013199","journal-title":"Cancer Cell"},{"issue":"3","key":"10077_CR245","first-page":"3407","volume":"18","author":"W Liang","year":"2019","unstructured":"Liang W et al (2019) Artemisinin induced reversal of EMT affects the molecular biological activity of ovarian cancer SKOV3 cell lines. Oncol Lett 18(3):3407\u20133414","journal-title":"Oncol Lett"},{"key":"10077_CR246","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.ebiom.2016.11.026","volume":"14","author":"X Li","year":"2016","unstructured":"Li X et al (2016) Preclinical efficacy and safety assessment of artemisinin-chemotherapeutic agent conjugates for ovarian cancer. EBioMedicine 14:44\u201354","journal-title":"EBioMedicine"},{"issue":"18","key":"10077_CR247","doi-asserted-by":"crossref","first-page":"8742","DOI":"10.1158\/0008-5472.CAN-06-2490","volume":"67","author":"JT Buijs","year":"2007","unstructured":"Buijs JT et al (2007) Bone morphogenetic protein 7 in the development and treatment of bone metastases from breast cancer. Cancer Res 67(18):8742\u20138751","journal-title":"Cancer Res"},{"issue":"3","key":"10077_CR248","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.2353\/ajpath.2007.070168","volume":"171","author":"JT Buijs","year":"2007","unstructured":"Buijs JT et al (2007) BMP7, a putative regulator of epithelial homeostasis in the human prostate, is a potent inhibitor of prostate cancer bone metastasis in vivo. Am J Pathol 171(3):1047\u20131057","journal-title":"Am J Pathol"},{"issue":"1","key":"10077_CR249","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ccell.2018.12.002","volume":"35","author":"D Ishay-Ronen","year":"2019","unstructured":"Ishay-Ronen D et al (2019) Gain fat\u2014lose metastasis: converting invasive breast cancer cells into adipocytes inhibits cancer metastasis. Cancer Cell 35(1):17\u201332","journal-title":"Cancer Cell"},{"issue":"3","key":"10077_CR250","doi-asserted-by":"crossref","first-page":"321","DOI":"10.15252\/embr.201439333","volume":"16","author":"D Mathow","year":"2015","unstructured":"Mathow D et al (2015) Zeb1 affects epithelial cell adhesion by diverting glycosphingolipid metabolism. EMBO Rep 16(3):321\u2013331","journal-title":"EMBO Rep"},{"issue":"7","key":"10077_CR251","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1158\/0008-5472.CAN-17-2834","volume":"78","author":"A Schwab","year":"2018","unstructured":"Schwab A et al (2018) Polyol pathway links glucose metabolism to the aggressiveness of cancer cells. Cancer Res 78(7):1604\u20131618","journal-title":"Cancer Res"},{"issue":"11","key":"10077_CR252","first-page":"e143247","volume":"5","author":"JR Brown","year":"2020","unstructured":"Brown JR et al (2020) Phase II clinical trial of metformin as a cancer stem cell\u2013targeting agent in ovarian cancer. JCI Insight 5(11):e143247","journal-title":"JCI Insight"},{"issue":"6","key":"10077_CR253","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1177\/0192623311416259","volume":"39","author":"MJ Anderton","year":"2011","unstructured":"Anderton MJ et al (2011) Induction of heart valve lesions by small-molecule ALK5 inhibitors. Toxicol Pathol 39(6):916\u2013924","journal-title":"Toxicol Pathol"},{"issue":"4","key":"10077_CR254","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/j.immuni.2019.03.024","volume":"50","author":"E Batlle","year":"2019","unstructured":"Batlle E, Massagu\u00e9 J (2019) Transforming growth factor-\u03b2 signaling in immunity and cancer. Immunity 50(4):924\u2013940","journal-title":"Immunity"},{"issue":"3","key":"10077_CR255","doi-asserted-by":"crossref","first-page":"e90353","DOI":"10.1371\/journal.pone.0090353","volume":"9","author":"JC Morris","year":"2014","unstructured":"Morris JC et al (2014) Phase I study of GC1008 (fresolimumab): a human anti-transforming growth factor-beta (TGF\u03b2) monoclonal antibody in patients with advanced malignant melanoma or renal cell carcinoma. PLoS ONE 9(3):e90353","journal-title":"PLoS ONE"},{"issue":"11","key":"10077_CR256","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1158\/1078-0432.CCR-17-3322","volume":"24","author":"SC Formenti","year":"2018","unstructured":"Formenti SC et al (2018) Focal irradiation and systemic TGF\u03b2 blockade in metastatic breast cancer. Clin Cancer Res 24(11):2493\u20132504","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10077_CR257","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1002\/jbmr.3617","volume":"34","author":"JT Tauer","year":"2019","unstructured":"Tauer JT, Abdullah S, Rauch F (2019) Effect of anti-TGF-beta treatment in a mouse model of severe osteogenesis imperfecta. J Bone Miner Res 34(2):207\u2013214","journal-title":"J Bone Miner Res"},{"issue":"4","key":"10077_CR258","doi-asserted-by":"crossref","first-page":"e398","DOI":"10.1111\/ajco.12584","volume":"12","author":"SW Lee","year":"2016","unstructured":"Lee SW et al (2016) Bone mineral density in women treated for various types of gynecological cancer. Asia-Pacific J Clin Oncol 12(4):e398\u2013e404","journal-title":"Asia-Pacific J Clin Oncol"},{"key":"10077_CR259","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2017-2800","author":"O D'Cruz","year":"2017","unstructured":"D\u2019Cruz O et al (2017) Transforming growth factor-beta 2 (TGF-\u03b22) antisense oligonucleotide (ASO) OT-101 synergizes with chemotherapy in preclinical tumor models. AACR. https:\/\/doi.org\/10.1158\/1538-7445.AM2017-2800","journal-title":"AACR"},{"issue":"2","key":"10077_CR260","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1158\/0008-5472.CAN-07-2307","volume":"68","author":"LA Van Aarsen","year":"2008","unstructured":"Van Aarsen LA et al (2008) Antibody-mediated blockade of integrin alpha v beta 6 inhibits tumor progression in vivo by a transforming growth factor-beta-regulated mechanism. Cancer Res 68(2):561\u2013570","journal-title":"Cancer Res"},{"issue":"1","key":"10077_CR261","doi-asserted-by":"crossref","first-page":"4545","DOI":"10.1038\/s41467-020-17811-3","volume":"11","author":"G de Streel","year":"2020","unstructured":"de Streel G et al (2020) Selective inhibition of TGF-beta1 produced by GARP-expressing tregs overcomes resistance to PD-1\/PD-L1 blockade in cancer. Nat Commun 11(1):4545","journal-title":"Nat Commun"},{"issue":"17","key":"10077_CR262","doi-asserted-by":"crossref","first-page":"7173","DOI":"10.1074\/jbc.M116.768754","volume":"292","author":"SK Kim","year":"2017","unstructured":"Kim SK et al (2017) An engineered transforming growth factor \u03b2 (TGF-\u03b2) monomer that functions as a dominant negative to block TGF-\u03b2 signaling. J Biol Chem 292(17):7173\u20137188","journal-title":"J Biol Chem"},{"issue":"1","key":"10077_CR263","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.canlet.2016.07.029","volume":"381","author":"G Gallo-Oller","year":"2016","unstructured":"Gallo-Oller G et al (2016) P144, a transforming growth factor beta inhibitor peptide, generates antitumoral effects and modifies SMAD7 and SKI levels in human glioblastoma cell lines. Cancer Lett 381(1):67\u201375","journal-title":"Cancer Lett"},{"issue":"49","key":"10077_CR264","doi-asserted-by":"crossref","first-page":"11755","DOI":"10.1021\/bi901528w","volume":"48","author":"V Mendoza","year":"2009","unstructured":"Mendoza V et al (2009) Betaglycan has two independent domains required for high affinity TGF-\u03b2 binding: proteolytic cleavage separates the domains and inactivates the neutralizing activity of the soluble receptor. Biochemistry 48(49):11755\u201311765","journal-title":"Biochemistry"},{"issue":"18","key":"10077_CR265","doi-asserted-by":"crossref","first-page":"5458","DOI":"10.1158\/1078-0432.CCR-19-1065","volume":"25","author":"JJ Tao","year":"2019","unstructured":"Tao JJ et al (2019) First-in-human phase I study of the activin A inhibitor, STM 434, in patients with granulosa cell ovarian cancer and other advanced solid tumors. Clin Cancer Res 25(18):5458","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10077_CR266","doi-asserted-by":"crossref","first-page":"323","DOI":"10.4062\/biomolther.2013.072","volume":"21","author":"YY Sheen","year":"2013","unstructured":"Sheen YY et al (2013) Targeting the transforming growth factor-\u03b2 signaling in cancer therapy. Biomol Ther 21(5):323\u2013331","journal-title":"Biomol Ther"},{"issue":"8","key":"10077_CR267","doi-asserted-by":"crossref","first-page":"260","DOI":"10.3390\/cancers10080260","volume":"10","author":"Q Zhang","year":"2018","unstructured":"Zhang Q et al (2018) LY2157299 monohydrate, a TGF-\u03b2R1 inhibitor, suppresses tumor growth and ascites development in ovarian cancer. Cancers 10(8):260","journal-title":"Cancers"},{"issue":"6","key":"10077_CR268","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1158\/0008-5472.CAN-10-2941","volume":"71","author":"EC Connolly","year":"2011","unstructured":"Connolly EC et al (2011) Outgrowth of drug-resistant carcinomas expressing markers of tumor aggression after long-term T\u03b2RI\/II kinase inhibition with LY2109761. Cancer Res 71(6):2339\u20132349","journal-title":"Cancer Res"},{"issue":"2","key":"10077_CR269","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1124\/mol.118.112946","volume":"95","author":"LC Spender","year":"2019","unstructured":"Spender LC et al (2019) Preclinical evaluation of AZ12601011 and AZ12799734, inhibitors of transforming growth factor \u03b2 superfamily type 1 receptors. Mol Pharmacol 95(2):222\u2013234","journal-title":"Mol Pharmacol"},{"issue":"2","key":"10077_CR270","doi-asserted-by":"crossref","first-page":"e1539613","DOI":"10.1080\/2162402X.2018.1539613","volume":"8","author":"D Newsted","year":"2019","unstructured":"Newsted D et al (2019) Blockade of TGF-\u03b2 signaling with novel synthetic antibodies limits immune exclusion and improves chemotherapy response in metastatic ovarian cancer models. Oncoimmunology 8(2):e1539613","journal-title":"Oncoimmunology"},{"issue":"4","key":"10077_CR271","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1093\/cvr\/cvn355","volume":"81","author":"E-H Yao","year":"2009","unstructured":"Yao E-H et al (2009) A pyrrole\u2013imidazole polyamide targeting transforming growth factor-\u03b21 inhibits restenosis and preserves endothelialization in the injured artery. Cardiovasc Res 81(4):797\u2013804","journal-title":"Cardiovasc Res"},{"issue":"3","key":"10077_CR272","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/mt.2009.263","volume":"18","author":"M Chen","year":"2010","unstructured":"Chen M et al (2010) Pretranscriptional regulation of Tgf-\u03b21 by PI polyamide prevents scarring and accelerates wound healing of the cornea after exposure to alkali. Mol Ther 18(3):519\u2013527","journal-title":"Mol Ther"},{"issue":"1","key":"10077_CR273","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/ki.2010.330","volume":"79","author":"H Matsuda","year":"2011","unstructured":"Matsuda H et al (2011) Transcriptional inhibition of progressive renal disease by gene silencing pyrrole\u2013imidazole polyamide targeting of the transforming growth factor-\u03b21 promoter. Kidney Int 79(1):46\u201356","journal-title":"Kidney Int"},{"issue":"10","key":"10077_CR274","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1038\/jid.2011.150","volume":"131","author":"H Washio","year":"2011","unstructured":"Washio H et al (2011) Transcriptional inhibition of hypertrophic scars by a gene silencer, pyrrole\u2013imidazole polyamide, targeting the TGF-\u03b21 promoter. J Invest Dermatol 131(10):1987\u20131995","journal-title":"J Invest Dermatol"},{"issue":"5","key":"10077_CR275","doi-asserted-by":"crossref","first-page":"e0125295","DOI":"10.1371\/journal.pone.0125295","volume":"10","author":"J Igarashi","year":"2015","unstructured":"Igarashi J et al (2015) Preclinical study of novel gene silencer pyrrole-imidazole polyamide targeting human TGF-\u03b21 promoter for hypertrophic scars in a common marmoset primate model. PLoS ONE 10(5):e0125295","journal-title":"PLoS ONE"},{"issue":"4","key":"10077_CR276","doi-asserted-by":"crossref","first-page":"320","DOI":"10.3390\/cells8040320","volume":"8","author":"HS Sow","year":"2019","unstructured":"Sow HS et al (2019) Combined inhibition of TGF-\u03b2 signaling and the PD-L1 immune checkpoint is differentially effective in tumor models. Cells 8(4):320","journal-title":"Cells"},{"issue":"7693","key":"10077_CR277","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/nature25501","volume":"554","author":"S Mariathasan","year":"2018","unstructured":"Mariathasan S et al (2018) TGF\u03b2 attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature 554(7693):544\u2013548","journal-title":"Nature"},{"key":"10077_CR278","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aan5488","author":"Y Lan","year":"2018","unstructured":"Lan Y et al (2018) Enhanced preclinical antitumor activity of M7824, a bifunctional fusion protein simultaneously targeting PD-L1 and TGF-beta. Sci Transl Med. https:\/\/doi.org\/10.1126\/scitranslmed.aan5488","journal-title":"Sci Transl Med"},{"issue":"1","key":"10077_CR279","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1158\/1078-0432.CCR-09-1758","volume":"16","author":"L Wang","year":"2010","unstructured":"Wang L et al (2010) Immunotherapy for human renal cell carcinoma by adoptive transfer of autologous transforming growth factor \u03b2\u2013insensitive CD8+ T cells. Clin Cancer Res 16(1):164\u2013173","journal-title":"Clin Cancer Res"},{"issue":"12","key":"10077_CR280","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1038\/sj.cgt.7700975","volume":"13","author":"H Fakhrai","year":"2006","unstructured":"Fakhrai H et al (2006) Phase I clinical trial of a TGF-\u03b2 antisense-modified tumor cell vaccine in patients with advanced glioma. Cancer Gene Ther 13(12):1052\u20131060","journal-title":"Cancer Gene Ther"},{"issue":"1","key":"10077_CR281","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1158\/1078-0432.CCR-10-2195","volume":"17","author":"J Olivares","year":"2011","unstructured":"Olivares J et al (2011) Phase I trial of TGF-\u03b22 antisense GM-CSF gene-modified autologous tumor cell (TAG) vaccine. Clin Cancer Res 17(1):183\u2013192","journal-title":"Clin Cancer Res"},{"issue":"8","key":"10077_CR282","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1111\/liv.14113","volume":"39","author":"S Faivre","year":"2019","unstructured":"Faivre S et al (2019) Novel transforming growth factor beta receptor I kinase inhibitor galunisertib (LY2157299) in advanced hepatocellular carcinoma. Liver Int 39(8):1468\u20131477","journal-title":"Liver Int"},{"issue":"3","key":"10077_CR283","doi-asserted-by":"crossref","first-page":"e90353","DOI":"10.1371\/journal.pone.0090353","volume":"9","author":"JC Morris","year":"2014","unstructured":"Morris JC et al (2014) Phase I study of GC1008 (fresolimumab): a human anti-transforming growth factor-beta (TGFbeta) monoclonal antibody in patients with advanced malignant melanoma or renal cell carcinoma. PLoS ONE 9(3):e90353","journal-title":"PLoS ONE"},{"issue":"6","key":"10077_CR284","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.3892\/ijo.2014.2679","volume":"45","author":"A Cohn","year":"2014","unstructured":"Cohn A et al (2014) A phase I dose-escalation study to a predefined dose of a transforming growth factor-beta1 monoclonal antibody (TbetaM1) in patients with metastatic cancer. Int J Oncol 45(6):2221\u20132231","journal-title":"Int J Oncol"},{"key":"10077_CR285","unstructured":"Trials.gov c Phase I\/Ib study of NIS793 in combination With PDR001 in patients with advanced malignancies. ClinicalTrialsgov Identifier: NCT02947165"},{"issue":"1","key":"10077_CR286","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1093\/neuonc\/noq142","volume":"13","author":"U Bogdahn","year":"2011","unstructured":"Bogdahn U et al (2011) Targeted therapy for high-grade glioma with the TGF-beta2 inhibitor trabedersen: results of a randomized and controlled phase IIb study. Neuro Oncol 13(1):132\u2013142","journal-title":"Neuro Oncol"},{"key":"10077_CR287","unstructured":"Trials.gov C Study to determine the safety, tolerability, pharmacokinetics and RP2D of ABBV-151 as a single agent and in combination with ABBV-181 in participants with locally advanced or metastatic solid tumors. ClinicalTrialsgov Identifier: NCT03821935"},{"key":"10077_CR288","unstructured":"Timothy Yap1 DA, Debra Wood3, Jean-Fran\u00e7ois Denis3, Tina Gruosso3, Gilles Tremblay3, Maureen O\u2019Connor-McCourt3, Ria Ghosh3, Sandra Sinclair3, Paul Nadler3, Lilian Siu2 and Nehal Lakhani4 P856\u2005AVID200, first-in-class TGF-beta1 and beta3 selective inhibitor: results of a phase 1 monotherapy dose escalation study in solid tumors and evidence of target engagement in patients."},{"key":"10077_CR289","unstructured":"Vicki Leigh Keedy TMB, Jeffrey Melson Clarke, Herbert Hurwitz, Insun Baek, Ilho Ha, Chan-Young Ock, Su Youn Nam, Mina Kim, Neunggyu Park, Jung Yong Kim, Seong-Jin Kim Association of TGF-\u03b2 responsive signature with anti-tumor effect of vactosertib, a potent, oral TGF-\u03b2 receptor type I (TGFBRI) inhibitor in patients with advanced solid tumor. J Clin Oncol 36, no 15_suppl"},{"issue":"9","key":"10077_CR290","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1158\/1078-0432.CCR-15-1622","volume":"22","author":"LW Goff","year":"2016","unstructured":"Goff LW et al (2016) A phase I study of the anti-activin receptor-like kinase 1 (ALK-1) monoclonal antibody PF-03446962 in patients with advanced solid tumors. Clin Cancer Res 22(9):2146\u20132154","journal-title":"Clin Cancer Res"},{"issue":"29","key":"10077_CR291","doi-asserted-by":"crossref","first-page":"4721","DOI":"10.1200\/JCO.2005.05.5335","volume":"24","author":"J Nemunaitis","year":"2006","unstructured":"Nemunaitis J et al (2006) Phase II study of belagenpumatucel-L, a transforming growth factor beta-2 antisense gene-modified allogeneic tumor cell vaccine in non-small-cell lung cancer. J Clin Oncol 24(29):4721\u20134730","journal-title":"J Clin Oncol"},{"issue":"1","key":"10077_CR292","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1158\/1078-0432.CCR-10-2195","volume":"17","author":"J Olivares","year":"2011","unstructured":"Olivares J et al (2011) Phase I trial of TGF-beta 2 antisense GM-CSF gene-modified autologous tumor cell (TAG) vaccine. Clin Cancer Res 17(1):183\u2013192","journal-title":"Clin Cancer Res"}],"container-title":["Clinical &amp; Experimental Metastasis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10585-021-10077-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10585-021-10077-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10585-021-10077-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T21:57:16Z","timestamp":1671314236000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10585-021-10077-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,15]]},"references-count":292,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["10077"],"URL":"https:\/\/doi.org\/10.1007\/s10585-021-10077-z","relation":{},"ISSN":["0262-0898","1573-7276"],"issn-type":[{"value":"0262-0898","type":"print"},{"value":"1573-7276","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,15]]},"assertion":[{"value":"19 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 February 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no competing financial interests or conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}